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Abstract 
 It has long been known that in addition to disruptions in glucose 
homeostasis, individuals with insulin resistance have a breakdown in lipid 
dynamics, often manifested by elevated levels of circulating fatty acids (FA) 
together with accumulation of lipids in insulin-sensitive tissues, including 
skeletal muscle.  However, little is known about how common therapies used to 
treat insulin resistant individuals (such as Rosiglitazone and exercise training) 
improve skeletal muscle lipid and glucose metabolism.  Thus, the primary aim of 
the studies undertaken for this thesis was to enhance our understanding of the 
mechanisms by which Rosiglitazone and exercise training improve skeletal 
muscle lipid metabolism and insulin sensitivity in two distinct models of insulin 
resistance.  The first investigation determined the effect of chronic Rosiglitazone 
treatment on the accumulation of lipid metabolites and enzymatic regulators of 
lipid metabolism in the skeletal muscle of obese Zucker rats.  The observation 
that Rosiglitazone treatment exacerbated the accumulation of muscle ceramide 
and diacylglycerol in skeletal muscle, while improving glucose tolerance led to 
the conclusion that this insulin sensitising drug improves insulin sensitivity by 
mechanisms other than reduction of fatty acid metabolites in this tissue.  
Accordingly, the second investigation sought to identify an alternative 
mechanism by which Rosiglitazone treatment may improve skeletal muscle 
insulin sensitivity.   It was found that Rosiglitazone restored AMP-activated 
protein kinase (AMPK) α2 activity in the skeletal muscle of obese Zucker rats, 
providing a potential peroxisome proliferator activated receptor (PPAR) γ-
independent mechanism by which this drug may mediate its insulin-sensitising 
actions.  The final experiment undertaken for this thesis determined the 
independent and interactive effects on Rosiglitazone and exercise training on 
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various aspects of skeletal muscle glucose and lipid metabolism in a model of 
diet-induced insulin resistance, the high-fat fed rat.  Exercise training, but not 
Rosiglitazone treatment restored skeletal muscle insulin sensitivity in high-fat 
fed rats.  Improvements in insulin sensitivity with exercise training were 
associated with increased FA oxidation, increased AMPK activity and a 
normalisation of the expression of the Akt substrate, AS160.  In contrast, 
Rosiglitazone treatment was associated with increased FA uptake and 
decreased insulin-stimulated glucose uptake in skeletal muscle.  Exercise 
prevented the accumulation of skeletal muscle lipids in Rosiglitazone-treated 
animals when the two treatments were combined.  In summary, the results from 
the studies undertaken for this thesis provide novel information regarding the 
mechanisms by which two insulin-sensitising therapies, exercise training and 
Rosiglitazone treatment, act to improve glucose and lipid metabolism in skeletal 
muscle.    
 
 
  
 2
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER ONE: Literature Review 
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1.1  The Role of Skeletal Muscle in Type 2 Diabetes 
 
The prevalence of type 2 diabetes mellitus is increasing at an alarming 
rate with the total number of cases expected to reach 300 million world-wide by 
2025 (Zimmet et al. 2001).  Consequently, intense research efforts have 
focused on the development of improved treatments for this disease.  Type 2 
diabetes is a progressive metabolic disorder that results from the interplay of 
many environmental and genetic factors (Malecki and Klupa 2005).  Its 
progression involves several organs that are responsible for whole-body 
metabolic control, from central regulators (i.e. the hypothalamus) to peripheral 
organs (including adipose tissue, the liver, pancreas and skeletal muscle).  
Metabolic defects in any one or a combination of these organs can lead to 
impaired delivery of glucose from the circulation to insulin-sensitive tissues, 
which eventually results in the accumulation of glucose in the blood.  Chronic 
hyperglycemia leads to the secondary complications of diabetes, which include 
cardiovascular disease, kidney failure, blindness and neuropathy.  Accordingly, 
current interventions for the treatment of patients with diabetes are targeted to 
restore euglycemia, either by improving glucose uptake by tissues in response 
to insulin, or by stimulating glucose uptake by insulin-independent mechanisms 
(Clement 2004).   
Several organs act to dispose of blood glucose in response to insulin.  
However, skeletal muscle is the principal site of glucose uptake, accounting for 
up to 80% of glucose disposal under insulin-stimulated conditions (DeFronzo et 
al. 1985).  Although the primary defect(s) leading to the development of type 2 
diabetes is unknown, impairment of muscle glucose uptake in response to 
insulin is thought to be a major contributor to this disease.  Skeletal muscle also 
has the capacity to take up and store significant amounts of glucose via insulin-
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independent mechanisms (Richter et al. 2001).  Therefore, the potential for this 
tissue to dispose of, and store large amounts of glucose by multiple pathways 
makes it an excellent target for the treatment of type 2 diabetes. 
1.2  Skeletal Muscle Glucose Uptake: Molecular Pathways  
Glucose uptake into skeletal muscle is mediated by two distinct 
molecular signalling pathways.  One pathway requires insulin for its initiation 
and is termed “insulin-dependent”.  The other pathway is “insulin-independent”, 
and can activate glucose transport in response to other stimuli such as exercise 
and hypoxia.  Both pathways are important targets for improved glucose 
homeostasis. 
1.2.1 Insulin-dependent glucose uptake 
The initial steps in the molecular pathway that lead to increased skeletal 
muscle glucose uptake in response to insulin have been well-characterised 
(Thong et al. 2005), and are shown in Figure 1.1.  When insulin is secreted by 
the pancreas in response to an elevated blood glucose concentration, it signals 
the need for glucose uptake in skeletal muscle by binding to the 
extramyocellular α-subunit of the insulin receptor (IR).  The signal is then 
transmitted intracellularly to the β-subunit by a conformational change, which 
enables autophosphorylation of the IR, followed by tyrosine phosphorylation of 
intracellular proteins known as insulin-receptor substrates (IRS).  Tyrosine-
phosphorylated IRS binds to a specific group of proteins containing src-
homology-2 domains (SH2), the most important of which for insulin’s metabolic 
actions is phosphatidylinositol 3-kinase (PI3K).     
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 Figure 1. 1  A schematic representation of the molecular pathway leading 
to insulin-stimulated glucose uptake in skeletal muscle. 
The binding of insulin to the insulin receptor initiates a series of conformational 
changes and phosphorylation events involving several intracellular proteins.  
IRS, Insulin receptor substrates; PI3-K, phosphatidylinositol-3-kinase; PIP2, 
phosphatidylinositol-3,4-bisphosphate; PIP3, phosphatidylinositol-3,4,5-
triphosphate; PDK, phosphatidylinositol-dependent protein kinase; PKC, protein 
kinase C; Akt, protein kinase B (PKB); AS160, Akt substrate of 160 kDa; 
GLUT4, Glucose Transporter 4; HK, hexokinase. 
 
 PI3K promotes glucose uptake and several other processes involved in 
carbohydrate and lipid metabolism, via its lipid product 3, 4, 5-
phosphatidylinositol (PIP3).  In turn, PIP3 activates a number of serine and 
threonine kinases, including PI-dependent protein kinases (PDK), Akt/protein 
kinase B, and protein kinase C (PKC).  Activation of Akt and/or PKC leads to 
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the translocation of glucose transporters (GLUT4) from intracellular stores to the 
plasma membrane, allowing for the facilitated diffusion of glucose into the cell 
from the intercellular compartment. 
Although the signalling mechanisms proximal to the insulin receptor have 
been well-established, the signalling pathways downstream of Akt/PKC that 
lead to GLUT4 translocation to the plasma membrane are still under debate 
(Dugani and Klip 2005).  The precise mechanisms that lead to the cycling of 
GLUT4 vesicles between the intracellular compartment and the plasma 
membrane are complex and outside the scope of this review [for review see 
(Dugani and Klip 2005)].  Briefly, it is likely that Akt [predominantly the Akt2 
isoform; (Bae et al. 2003)] is recruited to GLUT4-containing vesicles, where it 
phosphorylates several vesicle component proteins, including GLUT4 itself 
(Kupriyanova and Kandror 1999).  In particular, the Akt substrate of 160-kDa 
(AS160) appears to be an important regulator of vesicle translocation (Miinea et 
al. 2005) by retaining GLUT4 in the basal state until phosphorylation by Akt 
signals the need for vesicle mobilisation to the plasma membrane (Eguez et al. 
2005).    
There is also evidence that the atypical PKC (aPKC) isoforms, PKC ζ 
and λ, play an important role in the translocation of GLUT4.  It has been 
demonstrated in muscle cells that increasing the expression of PKCζ stimulates 
glucose transport, whereas decreasing the expression of this isoform has an 
inhibitory effect on this process (Bandyopadhyay et al. 1997).  More recently, 
aPKC has been implicated in both the mobilisation of GLUT4 (Imamura et al. 
2003) and its fusion to the plasma membrane (Hodgkinson et al. 2005; Lizunov 
et al. 2005). 
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1.2.2 Insulin-independent glucose uptake: AMP-activated protein 
kinase  
In the absence of insulin, skeletal muscle glucose transport can be 
initiated in response to increased demand and/or depletion of energy stores.  A 
drop in myocellular energy status through events such as muscle contraction or 
hypoxia can activate pathways that reduce cellular energy expenditure and 
increase its production in order to restore energy balance.  The key enzyme 
responsible for these metabolic changes is the AMP-activated protein kinase 
(AMPK). 
 AMPK is a heterotrimeric protein that is comprised of a catalytic α subunit 
and regulatory β and γ subunits (Kahn et al. 2005).  Two isoforms of the 
catalytic subunit, α1 and α2, are expressed in skeletal muscle and encoded by 
different genes.  Studies using rodent knockout models indicate that the α1 and 
α2 isoforms play distinct roles in the regulation of whole-body glucose 
homeostasis (Viollet et al. 2003), though their precise roles in skeletal muscle 
glucose metabolism remain unclear. 
As depicted in Figure 1.2, AMPK is highly sensitive to, and allosterically 
activated by 5’ AMP.  This activation is inhibited by ATP, which makes the 
AMP/ATP ratio a good indicator of cellular energy status and AMPK activation 
(Winder and Hardie 1999; Fujii et al. 2006).  Any cellular event that decreases 
ATP synthesis (i.e. hypoxia, heat stress) or increases ATP consumption (i.e. 
muscle contraction) activates the AMPK signalling pathway.   
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Figure 1. 2   A schematic representation of the insulin-independent 
regulation of AMP-activated protein kinase (AMPK) pathway in skeletal 
muscle. 
Energy-depleting events such as muscle contraction or pharmacological 
treatment with AICAR activate a number of signal transduction pathways that 
lead to AMPK activation and insulin-independent GLUT4 translocation.  AICAR, 
5-aminoimidazole-4 carboxamide; ZMP, AICAR monophosphate; CaMKK, 
calmodulin-dependent protein kinase kinase; LKB1, AMP kinase kinase 
 
Although AMP alone can allosterically activate AMPK, activation can also 
occur covalently through phosphorylation of its Thr172 residue by an upstream 
kinase that was recently identified as LKB1 (Hawley et al. 2003).  Since LKB1 
itself is allosterically activated by AMP, and the binding of AMP to AMPK makes 
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it a better substrate for LKB1, the result is a highly amplified activation cascade 
sensitive to small changes in AMP.   
The AMPK signalling cascade is further amplified during muscle 
contraction by the Ca2+/calmodulin system (Hawley et al. 2005).  The rise in 
intracellular [Ca2+] that occurs during contraction activates calmodulin-
dependent protein kinase kinase (CaMKK), which then phosphorylates AMPK at 
its Thr172 residue (Hawley et al. 1995). Ca2+/calmodulin-dependent AMPK 
activation is additive to the effects of AMP (Salt et al. 1998; Hawley et al. 2005) 
and is fully functional in cells that are deficient in LKB1 (Hawley et al. 2005). 
Although the precise mechanism by which AMPK stimulates glucose 
transport is currently unknown, is it believed that activation of this kinase results 
in the phosphorylation of unknown target proteins, which leads to the 
translocation of GLUT4 protein to the plasma membrane (Winder and Hardie 
1999; Fujii et al. 2006).  Evidence to support this theory has come from studies 
using the pharmacological activator of AMPK, 5-aminoimidazole-4 carboxamide 
(AICAR).  AICAR is transported across the cell membrane and is then 
converted to the AMP analogue, ZMP, inside the intracellular compartment.  
ZMP has the ability to activate both LKB1 and AMPK in the same manner as 
AMP, making it a useful tool to study AMPK action without inducing the multiple 
confounding factors involved with increasing cellular AMP levels.  
An early study reported that in perfused skeletal muscle, glucose uptake 
across the rat hindlimb was increased two-fold in response to AICAR (Merrill et 
al. 1997).  Further work demonstrated that AICAR-stimulated muscle glucose 
uptake was independent of insulin, and was not inhibited by the PI3K inhibitor 
wortmannin (Hayashi et al. 1998).  More mechanistic investigations using 
fluorescent labelling techniques revealed that AICAR-induced glucose transport 
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was indeed associated with the translocation of GLUT4 protein to the 
sarcolemma (Russell et al. 1999).  Evidence that PKC may be involved in 
AICAR-induced glucose transport comes from work demonstrating that PKCζ 
activity is increased in myotubes treated with AICAR, and AICAR-induced 
glucose transport is inhibited by a PKCζ inhibitor (Chen et al. 2002).  
Interestingly, the activation of PKCζ by AICAR in that study (Chen et al. 2002) 
was similar in magnitude to the activation induced by insulin, but was not 
sensitive to wortmannin, indicating a point of convergence in the insulin-
dependent and -independent pathways. 
Although this review will focus on the role of AMPK in facilitating glucose 
transport into skeletal muscle, it should be noted that the AMPK signalling 
pathway is not the only contributor to insulin-independent glucose uptake in this 
tissue.  Muscle contraction induces the activation of several signalling 
mechanisms that have been associated with increased GLUT4 translocation 
including Ca2+/calmodulin, nitric oxide and PKC  (Jessen and Goodyear 2005).  
Jorgensen et al. (2004) recently reported no effect on contraction-induced 
glucose transport in transgenic mice with a gene knockout of either the AMPK 
α1 or α2 catalytic subunits.  These workers concluded that other contraction-
induced mechanisms may compensate for the loss of a single AMPK isoform.  It 
is also likely that the remaining AMPK isoform compensates for the loss of its 
counterpart, as evidenced by the finding that the expression of the AMPKα1 
isoform is doubled in AMPK α2 knockout mice (Jorgensen et al. 2004).  The 
simultaneous knockout of both isoforms has not yet been studied. 
 Although its importance in contraction-stimulated glucose uptake is 
debatable, the ability of AMPK to stimulate skeletal muscle glucose uptake 
makes it an attractive target for the treatment of type 2 diabetes (Winder 2000; 
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Musi and Goodyear 2002).   In addition to its role in insulin-independent glucose 
uptake, chronic AMPK activation has the ability to increase insulin-stimulated 
GLUT4 translocation in muscle, possibly due to an increase in GLUT4 protein 
expression (Buhl et al. 2001).  Furthermore, the expression of AMPK, and its 
activation in response to exercise appears to be normal in the muscle of 
individuals with type 2 diabetes (Musi et al. 2001).  Taken together, the results 
from these studies identify AMPK activation as a potential therapeutic target for 
the enhancement of glucose uptake by both insulin-dependent and -
independent means.  
 
1.3 Insulin Resistance in Skeletal Muscle 
1.3.1 General definition/ characteristics 
 Insulin mediates a number of cellular processes, making insulin 
resistance a multifaceted syndrome (Wilcox 2005).  Insulin resistance is 
generally defined as an attenuated physiological response to a standard or 
maximal dose of insulin.  However, for the purposes of this review, the definition 
of insulin resistance will be narrowed to the inability to maintain glucose 
homeostasis in response to normal circulating insulin levels.   
 In individuals with insulin resistance, the failure of insulin to induce 
adequate glucose uptake and storage in peripheral tissues such as skeletal 
muscle and adipose, and to inhibit hepatic glucose output, leads to a rise in 
blood glucose concentration.  Initially, the body may compensate for impaired 
insulin sensitivity by increasing pancreatic insulin secretion, thus allowing blood 
glucose concentration to be maintained.  If this state of insulin resistance 
progresses, hyperinsulinemia may no longer compensate for impaired insulin 
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action, resulting in hyperglycemia and eventually the development of type 2 
diabetes and its secondary complications (Saltiel 2000; Unger and Orci 2001).  
 The initial defect(s) that result in impaired glucose homeostasis 
secondary to insulin resistance are not clear.  However, since skeletal muscle is 
responsible for the majority of insulin-stimulated glucose disposal (DeFronzo et 
al. 1985), impaired insulin action in this tissue likely plays a major role in the 
impaired glucose homeostasis associated with insulin resistance.  Indeed, 
muscle from insulin resistant individuals with type 2 diabetes (Andreasson et al. 
1991) and rodent models of insulin resistance (Zierath et al. 1997) 
demonstrates marked reductions in insulin-stimulated transport of the non-
metabolised glucose analogue 3-O-methylglucose. 
 
1.3.2 Molecular mechanisms associated with skeletal muscle insulin 
resistance 
 In individuals with type 2 diabetes, impaired insulin-stimulated glucose 
uptake in skeletal muscle is associated with inadequate recruitment of GLUT4 
to the plasma membrane (Bjornholm and Zierath 2005).  Reduced membrane 
GLUT4 content can occur despite normal expression of GLUT4 protein (Zierath 
et al. 1997; Zierath et al. 2000), indicating that signalling events that lead to 
GLUT4 translocation may be causally related to muscle insulin resistance.  
Defective GLUT4 translocation in skeletal muscle may result from 
downregulation of one or more components of the insulin signal transduction 
pathway, or from disruption of mechanical events that allow for the 
translocation/insertion of GLUT4 in the plasma membrane.  It is possible that 
redistribution of GLUT4 to inaccessible intracellular compartments inhibits 
GLUT4 trafficking and translocation to the plasma membrane in individuals with 
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type 2 diabetes (Garvey et al. 1998).  However, GLUT4 translocation in 
response to contraction and hypoxia is normal in insulin-resistant rats (Zierath 
et al. 1997), suggesting that impaired insulin signalling is at least partially 
responsible for skeletal muscle insulin resistance.  
 The role of the insulin receptor in skeletal muscle insulin resistance is 
equivocal, as some studies have reported a decrease (Nolan et al. 1994) or no 
change (Krook et al. 2000) in its expression and insulin-stimulated 
phosphorylation in the skeletal muscle of insulin-resistant subjects.  However, a 
number of defects to the insulin signalling cascade have been identified in 
insulin resistant skeletal muscle.    Insulin-stimulated activation of the signalling 
cascade components directly downstream of the insulin receptor, IRS-1 and 
PI3-kinase, are impaired in the muscle of individuals with type 2 diabetes 
(Bjornholm et al. 1997; Krook et al. 2000; Bjornholm and Zierath 2005).   
Aberrant signalling at the level of IRS-1 and PI3-kinase appears to be due to 
loss of function rather than reduced protein expression (Bjornholm and Zierath 
2005).  Further downstream, Akt activation in response to physiological insulin 
concentrations is normal in individuals with type 2 diabetes (Krook et al. 1998; 
Kim et al. 1999),  but appears to be blunted at higher (60 nM) insulin 
concentrations (Krook et al. 1998).  Reduced insulin-stimulated Akt activity in 
skeletal muscle from individuals with type 2 diabetes was recently attributed to 
decreased phosphorylation of this enzyme at Thr308, and was associated with 
decreased Akt-mediated AS160 phosphorylation (Karlsson et al. 2005b).  In 
addition to impairments in the classic insulin signalling cascade, there is also 
evidence that downregulation of aPKC isoforms may be involved in the 
aetiology of skeletal muscle insulin resistance (Farese 2002).  Defective insulin-
stimulated PKCλ/ζ activity has been observed in insulin resistant and diabetic 
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individuals (Beeson et al. 2003; Kim et al. 2003b), as well as rodent models of 
insulin resistance (Kanoh et al. 2001). 
 It is apparent that defects in insulin resistant muscle have been found at 
virtually every known step of the signalling pathway that ultimately leads to 
GLUT4 translocation.  However, the extent to which these alterations in 
signalling are causative in the overall development of insulin resistance is 
unknown.  Although there is undoubtedly a genetic contribution to the aetiology 
of insulin resistance and type 2 diabetes, single-gene mutations that result in 
impaired insulin signalling are very rare and account for a minority of all cases 
(So et al. 2000).  Rather, it is likely that the onset of insulin resistance is a result 
of complex interactions between genetic susceptibility and a number of 
environmental factors (So et al. 2000; Beck-Nielsen et al. 2003).  In fact, 
environmental factors are believed to outweigh those from genetic contributions 
in causing type 2 diabetes, with the strongest environmental predictor of this 
disease state being obesity (Beck-Nielsen et al. 2003).   The robust association 
between the increasing world-wide prevalence of both obesity and diabetes 
(Golay and Ybarra 2005), has prompted some to refer to this co-existence of 
conditions as “diabesity” (Shafrir 1996).   
  
1.4 Intramyocellular Lipids and Insulin Resistance 
1.4.1 Ectopic lipid deposition and lipotoxicity 
 Given the strong epidemiological association between obesity and 
diabetes (Beck-Nielsen et al. 2003; Golay and Ybarra 2005), it is plausible that 
one or more of the physiological abnormalities associated with obesity is 
causally related to the onset of type 2 diabetes.  Obesity is associated with 
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alterations in lipid metabolism such as hyperlipidemia and the increased storage 
of lipids in insulin-sensitive tissues such as liver and skeletal muscle (Sharma 
2006).  The observation that increased lipid availability may be causally related 
to impaired glucose metabolism and insulin resistance in skeletal muscle was 
made some time ago (Randle et al. 1963).  Since then, evidence has 
accumulated to suggest that defects in skeletal muscle insulin signalling may be 
secondary to altered lipid metabolism (Schmitz-Peiffer 2000).  
 Lipid uptake and storage by skeletal muscle is essential as a source of 
energy and for normal muscle function (Kiens 2006).   However, conditions 
which promote excessive intracellular lipid accumulation due to lipid oversupply 
(such as obesity, high fat diet or lipid infusion) can induce insulin resistance in 
this tissue [(McGarry 2002) see figure 1.3].   Impaired cellular function as a 
result of excessive lipid accumulation is referred to as “lipotoxicity” (Russell 
2004).  Bachmann et al. (2001) demonstrated that increased lipid availability 
due to either acute lipid infusion or a chronic high-fat diet increased 
intramuscular lipid content and impaired insulin sensitivity.  More recently, 
impaired insulin signalling in skeletal muscle following lipid infusion in healthy 
individuals was observed to be dose-dependent (Belfort et al. 2005).  Similar 
observations have been made in rodent models of insulin resistance, where 
both high-fat feeding or pre-incubation of muscle strips in 1 mM palmitate were 
associated with accumulation of lipids and impaired insulin action (Thompson et 
al. 2000).   
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 Figure 1. 3  Inverse correlation between intramyocellular lipid (IMCL) and 
the rate of insulin-stimulated glucose disposal (Rd). 
Soleus muscle IMCL was measured using 1H-magnetic resonance 
spectroscopy (MRS) in healthy individuals.  Rd was assessed during a 
hyperinsulinemic-euglycemic clamp.  BMI, body mass index.  Reproduced from 
McGarry (2002). 
  
 There is compelling evidence linking impaired lipid metabolism such as 
elevated plasma and tissue lipid levels, and impaired glucose homeostasis in 
individuals with obesity and type 2 diabetes (McGarry 2002).  However, it is 
unclear whether altered lipid metabolism is coincidental with the insulin resistant 
state, or causative in its development.  It has been hypothesised that the 
accumulation of lipid metabolites may directly or indirectly interfere with insulin 
signal transduction, thereby reducing skeletal muscle GLUT4 translocation and 
glucose uptake (Schmitz-Peiffer 2000).  The accumulation of lipid species within 
skeletal muscle is a result of the balance between FA uptake and utilisation.  
Therefore, a better understanding of the regulation of lipid transport and 
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metabolism may provide insight into the defects that lead to lipid-induced insulin 
resistance in skeletal muscle.    
1.4.2 Regulation of lipid transport and storage in skeletal muscle 
 Transport of FA from the circulation to the cytosol of skeletal muscle cells 
is likely the combined result of passive diffusion across the sarcolemma and 
protein-mediated membrane transport (Kiens 2006).  To date, three putative FA 
transport proteins have been identified in skeletal muscle: 1) fatty acid 
translocase (FAT/CD36), 2) plasma membrane fatty acid binding protein 
(FABPpm), and 3) fatty acid transport protein (FATP).  Of these transporters, 
FAT/CD36 has the most well-defined role in skeletal muscle lipid metabolism.  
Muscle-specific overexpression of FAT/CD36 in mice results in reduced plasma 
lipids as well as increased palmitate oxidation (Ibrahimi et al. 1999).  
Furthermore, skeletal muscle FAT/CD36 and triacylglycerol storage are 
increased in healthy, endurance trained athletes following consumption of a 
high fat diet (Cameron-Smith et al. 2003), in obese individuals (Bonen et al. 
2004), as well as in animal models of type 2 diabetes (Luiken et al. 2001).  In 
addition to chronic changes in the expression of this protein, it is likely that 
plasma membrane content of FAT/CD36 is regulated acutely via its 
translocation from intracellular compartments (Koonen et al. 2005).  Taken 
together, these observations indicate that FA transport into skeletal muscle is a 
highly regulated process that may influence whole-body lipid metabolism. 
 Once inside the cytosol, FA are activated in a reaction catalysed by acyl 
CoA synthetase (ACS), resulting in the formation of fatty acyl-CoA (FA-CoA) 
(Large et al. 2004) [see figure 1.4].  These FA-CoA esters can act as substrates 
for β-oxidation, be incorporated into intermediate lipid signalling molecules such 
as ceramide and diacylglycerol (DAG), or be stored as triacylglycerol (TAG).  
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FA-CoA that is targeted for oxidation must first cross the mitochondrial 
membrane in a process regulated by carnitine palmitoyl transferase (CPT1).  
Increased FA uptake, without a similar increase in oxidation would result in the 
accumulation of FA within the myocyte.  The capacity of skeletal muscle to 
oxidise FA is reduced in obesity and type 2 diabetes (Blaak 2004).  Decreased 
muscle FA oxidation combined with increased FA transport (described above) in 
obesity and diabetes provides a potential mechanism for the accumulation of 
lipid species in these conditions. 
 
 
Figure 1. 4  A schematic representation of the regulation of lipid uptake 
and storage in skeletal muscle.   
Fatty acids (FA) are transported across the sarcolemma and activated via 
formation of FA-CoA before entering the mitochondria for oxidation, or being 
transformed by the sphingolipid or glycerolipid synthesis pathways.  FAT/CD36, 
fatty acid translocase; ACS, acyl coenzyme A synthetase; GPAT, glycerol-3-
phosphate acyltransferase; DGAT, diacylglycerol acyltransferase; HSL, 
hormone-sensitive lipase; CPT1, carnitine palmitoyl transferase; PLC, 
phospholipase C; DAG, diacylglycerol; TAG, triacylglycerol 
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Excess FA-CoA that is not required to meet immediate energy demands 
through oxidation may be channelled through the glycerolipid or sphingolipid 
synthesis pathways.  An important intermediate product in the sphingolipid 
pathway is the signalling molecule ceramide, which is involved in the regulation 
of various cell functions (Summers 2006).  FA-CoA that is targeted for storage 
within the myocyte enters the glycerolipid synthesis pathway.  Glycerol-3-
phosphate acyltransferase (GPAT) catalyses the first committed step in this 
pathway, which results in the formation of the metabolically active lipid 
intermediate DAG.  DAG may also be produced from the hydrolysis of 
membrane phospholipids such as PI-4, 5-bisphosphate (PIP2) by the enzyme 
phospholipase C (PLC) (Nishizuka 1995).  The final step in glycerolipid 
synthesis that allows for the synthesis of TAG from DAG is regulated by 
diacylglycerol acyltransferase (DGAT).  TAG, which acts as the main storage 
form of lipids in muscle is deposited into lipid droplets where it may be 
hydrolysed back to DAG, and eventually to FA-CoA if required in other 
pathways.  The rate-limiting enzyme for TAG hydrolysis is hormone-sensitive 
lipase (HSL), which is a highly regulated protein thought to play an important 
role in the control of whole-body lipid metabolism (Holm et al. 2000). 
In summary, there is evidence that individuals with insulin resistance 
have increased uptake and possibly decreased FA oxidation which may result 
in the accumulation of lipid species in muscle.  Furthermore, it has been well-
established that excess lipid deposition in skeletal muscle is linked to insulin 
resistance.  Lipid storage in skeletal muscle is a highly regulated process, and 
disregulation of any of the steps involved in FA transport and storage may lead 
to the accumulation of one or more intramuscular lipid species.  Moreover, 
demonstrating the capacity of a specific lipid species to interfere with insulin 
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signal transduction would provide evidence for its accumulation to play a 
causative role in insulin resistance. 
1.4.3 Fatty acid-induced impairment of insulin signalling 
Triacylglycerol 
 Skeletal muscle TAG content is increased in obesity (Szczepaniak et al. 
1999) and type 2 diabetes (Goodpaster et al. 1997), and is inversely related to 
whole-body insulin sensitivity (Phillips et al. 1996; Pan et al. 1997a; Kelley et al. 
2002).  However, the mechanism by which stored TAG may interfere with 
insulin signal transduction remains elusive.  Evidence demonstrating a 
disassociation between muscle lipid content and insulin sensitivity suggests that 
TAG accumulation per se may not responsible for skeletal muscle insulin 
resistance (Goodpaster and Kelley 2002; van Loon and Goodpaster 2006).  
Endurance trained athletes are highly insulin sensitive (Staudacher et al. 2001) 
despite exhibiting elevated intramuscular triacylglycerol levels (Goodpaster et 
al. 2001).  Furthermore, Perdomo et al., (2004) demonstrated that increased 
palmitate oxidation due to CPT1 overexpression enhanced insulin sensitivity in 
palmitate-treated L6 myotubes despite intramyocellular lipid accumulation 
(Perdomo et al. 2004).  The capacity to oxidise lipids has also been 
demonstrated to be a better predictor of insulin sensitivity than muscle lipid 
status in type 2 diabetic [(Bruce et al. 2003) see figure 1.5] and obese 
individuals (Goodpaster et al. 2003). Such findings have lead to the proposal 
that the correlation between TAG content and insulin resistance may not 
represent a functional relationship (van Loon and Goodpaster 2006).  Rather, it 
has been suggested that intramuscular TAG acts as a marker for other, more 
metabolically active lipid metabolites that may directly impair insulin action in 
skeletal muscle (Goodpaster and Kelley 2002).   
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 Figure 1. 5   Relationship between glucose infusion rate (GIR) and 
markers of lipid status and skeletal muscle oxidative capacity. 
Measurements of A) % body fat; B) body mass index (BMI); C) plasma free fatty 
acid (FFA) concentration; D) maximal oxygen consumption (VO2max); E) citrate 
synthase activity and F) β- hydroxyacyl CoA dehydrogenase (HAD) activity 
were correlated to GIR during a euglycemic-hyperinsulinemic clamp.    
Reproduced from Bruce et al. (2003). 
 
Fatty acyl CoA 
 FA-CoA accumulates in skeletal muscle in response to lipid oversupply 
and has the potential to inhibit insulin signal transduction.  Unlike muscle TAG, 
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which is considered to be relatively inert, FA-CoA esters play an important role 
in the regulation of glucose and lipid metabolism as well as gene transcription 
(Faergeman and Knudsen 1997).  Studies in humans (Ellis et al. 2000; 
Houmard et al. 2002) and animals (Oakes et al. 1997a) have demonstrated a 
strong inverse correlation between FA-CoA levels and whole body insulin 
action.  There is evidence that FA-CoA may impair glucose metabolism through 
the inhibition of hexokinase (Thompson and Cooney 2000), which catalyses the 
first step in glucose storage and oxidation (see figure 1.6).  It has also been 
suggested that FA-CoA may inhibit insulin signal transduction through the 
activation of PKC isoforms either directly, or via the production of DAG (Hegarty 
et al. 2003).  Although the activation of atypical PKC (ζ, λ) isoforms are known 
to facilitate insulin-stimulated glucose uptake (see Figure 1.1), the conventional 
(α, β, γ) and novel (δ, ε, η, θ) isoforms contain lipid regulation domains (Newton 
2003), and their activation is associated with lipid-induced insulin resistance 
(Schmitz-Peiffer 2000).   
Diacylglycerol 
 As with FA-CoA, the production of DAG is associated with the activation 
of PKC isoforms that may inhibit insulin action.  The activation of conventional 
(cPKC) and novel (nPKC) PKC isoforms involves translocation and binding of 
the enzyme to the plasma membrane where it may interact with membrane-
embedded DAG and initiate downstream signalling events (Newton 2003).  
Thus, the measurement of membrane-associated PKC in muscle acts as a 
surrogate marker for PKC activation.   In healthy volunteers undergoing lipid 
infusion for 6 h, reduced rates of insulin-stimulated glucose disappearance were 
associated with increased muscle DAG content and membrane-associated 
PKCβII content (Itani et al. 2002).  Similarly, lipid infusion in rats resulted in 
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elevated muscle FA-CoA and DAG content concomitant with increased 
membrane-associated PKCθ (Yu et al. 2002).  Elevated sarcolemmal PKCθ 
content observed by Yu et al. (2002) was associated with increased 
phosphorylation of IRS-1 at ser307 which resulted in decreased IRS-1 tyrosine 
phosphorylation and IRS-1-associated PI3-kinase activity, providing a potential 
mechanism by which FA acutely impair insulin signal transduction.  
Overexpression of the cPKC isoforms α, βI, and γ provides evidence for PKC-
induced impairments upstream of IRS-1 as demonstrated by an increase in 
inhibitory serine and threonine phosphorylation of the IR in response to the 
DAG analogue, phorbol ester, under these conditions (Chin et al. 1993).  
Ceramide 
 In addition to DAG-induced inhibition of IR and IRS-1 activation, defects 
in insulin signal transduction at the level of Akt have been attributed to elevated 
muscle ceramide content (Summers 2006).   Skeletal muscle ceramide content 
is negatively correlated with insulin sensitivity (Straczkowski et al. 2004) and is 
increased in the skeletal muscle of obese insulin-resistant humans (Adams et 
al. 2004) and diabetic rodents (Gorska et al. 2004).  Evidence from 
investigations using cultured cells has demonstrated that ceramide’s inhibitory 
effect on insulin signalling is attributable to downregulation of Akt via 
mechanisms that are independent of IRS-1 or PI3-kinase (Zhou et al. 1998; 
Schubert et al. 2000).  This may occur as a result of dephosphorylation of Akt at 
ser473 due to ceramide-induced activation of protein phosphatase 2A (PP2A) 
(Chavez et al. 2003), or via PKC-induced inhibitory phosphorylation of Akt 
(Powell et al. 2004).  Further evidence for the involvement of ceramide in lipid-
induced insulin resistance has come from experiments using C2C12 myotubes 
that over-express the enzyme acid ceramidase, which catalyses the conversion 
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of ceramide to sphingosine.  Prevention of ceramide accumulation in this model 
abolished FA-induced impairment of insulin sensitivity in C2C12 myotubes, 
indicating that impairments to insulin action were ceramide-specific (Chavez et 
al. 2005). 
 
Figure 1. 6   Potential mechanisms by which lipid species inhibit insulin 
signal transduction in skeletal muscle.   
The accumulation of FA-CoA, DAG or ceramide may promote inhibitory 
phosphorylation events, or prevent stimulatory phosphorylation of insulin 
signalling proteins. G-6-P, glucose-6-phosphate; Pi, inhibitory phosphorylation; 
PP2A, protein phosphatase 2A 
 
1.4.4 Models of lipid-induced insulin resistance 
 Lipid oversupply leads to impairments in skeletal muscle insulin-
signalling and consequently, insulin resistance.   However, due to the 
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progressive nature of insulin resistance, it is likely that its clinical onset involves 
chronic metabolic adaptations involving gene transcription and protein 
expression, in addition to acute signalling events.   More detailed study of the 
impairments to lipid and glucose metabolism that result from chronically 
elevated lipid availability is made possible through the use of appropriate animal 
models of insulin-resistance.  The metabolic syndrome associated with the 
development of type 2 diabetes in humans is characterised by a number of 
chronic physiological conditions including obesity, dislipidemia, elevated 
skeletal muscle lipid storage, fasting hyperinsulinemia and hyperglycemia 
(Stumvoll et al. 2005).  Thus the results from investigations that employ animal 
models that exhibit some or all of these characteristics can be used to 
extrapolate to the human condition.   Such models may be obtained through the 
modification of genetic and/or lifestyle conditions, both of which are thought to 
contribute to the human disease state (Beck-Nielsen et al. 2003).  Two animal 
models that are commonly used in the study of lipid-induced insulin resistance 
are the obese (fa/fa) Zucker rat and high-fat fed rat. 
 
Obese (fa/fa) Zucker rat 
 The adipokine leptin is involved in the regulation of a number of 
physiological processes including the control of appetite, body mass and the 
storage and utilisation of lipids (Fruhbeck 2006).  The actions of leptin are 
mediated by its receptor (OB-R) which is present in nearly all tissues (Fruhbeck 
2006).  The leptin-unresponsive obese Zucker rat is homozygous for the fa 
mutation in the leptin receptor, and consequently exhibits a number of metabolic 
abnormalities.  Among these are obesity, dislipidemia, hyperinsulinemia, 
hyperglycemia and skeletal muscle insulin resistance (Unger and Orci 2001).   
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Compared with lean littermates, the obese Zucker rat also exhibits increased 
lipid deposition in non-adipose tissues such as skeletal muscle, making it one 
model for the study of lipid-induced insulin resistance in this tissue (Unger and 
Orci 2001). 
 
High-fat fed rodent 
 The consumption of a diet where fat comprises >30% of total energy 
intake is strongly related to obesity and the onset of obesity-related health 
problems such as type 2 diabetes (Lichtenstein et al. 1998).   In humans, 
consumption of a high-fat diet is associated with persistently elevated blood 
lipids, as well as abnormal glucose homeostasis and insulin resistance 
(Lombardo and Chicco 2006).  Similarly, mice and rats fed diets high in 
saturated, monounsaturated or polyunsaturated FA develop glucose 
intolerance, hyperinsulinemia and obesity (Lombardo and Chicco 2006).   High-
fat fed animals also exhibit increased skeletal muscle lipid storage and muscle-
specific insulin resistance (Oakes et al. 1997c).  Although genetic components 
may play a role in the onset of insulin resistance and type 2 diabetes, the 
rapidly increasing prevalence of this disease and its strong link to obesity 
suggest that lifestyle factors make an important contribution to its onset (Beck-
Nielsen et al. 2003).  Thus, the induction of insulin-resistance via high-fat 
feeding is a well-utilised model to investigate possible causes of lipid-induced 
insulin resistance in the absence of genetic modification. 
1.5 Treatments for Lipid-Induced Insulin Resistance 
 In humans, insulin resistance precedes type 2 diabetes by several 
decades, and the complications due to diabetes are often irreversible [(Saltiel 
2000) see figure 1.7].  Accordingly, it would seem prudent to attempt to improve 
 27
insulin resistance before the onset of diabetes and its secondary complications.  
Since skeletal muscle is the major source for insulin-stimulated glucose uptake, 
then any treatment targeted to improve glucose uptake in this tissue will 
improve whole-body glucose homeostasis.  Furthermore, given the causative 
link between abnormal lipid metabolism and impairments to insulin-stimulated 
glucose uptake, effective treatments to improve insulin resistance should have 
the ability to ameliorate aberrant lipid and glucose metabolism.   
 
Figure 1. 7   Timeline for the progression of metabolic impairments that 
lead to type 2 diabetes.   
Adapted from Saltiel, 2000. 
 
 Currently, there are several treatment options for patients with type 2 
diabetes, depending on the stage and severity/progression of their symptoms 
(Inzucchi 2002; Wysowski et al. 2003).  Sulfonylurea drugs (glyburide) and 
other secretagogues (repaglinide) act to improve glucose homeostasis by 
stimulating insulin secretion by the pancreatic β- cell.  Other treatment 
modalities include biguanides (metformin) and α-glucosidase inhibitors 
(acarbose), which decrease hepatic glucose production and decrease gut 
carbohydrate absorption, respectively.  A recent therapeutic option for 
individuals with insulin resistance or type 2 diabetes is the use of 
thiazolidinediones (TZDs), which act by increasing peripheral insulin sensitivity 
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and glucose disposal (Malinowski and Bolesta 2000).  All of these therapies are 
effective at lowering blood glucose concentrations, although they have distinct 
mechanisms of actions and molecular targets (Inzucchi 2002; Wysowski et al. 
2003).  However, none are without adverse side-effects, and the consequences 
of their long-term use, especially in the case of the TZDs, are largely unknown.  
Thus, significant effort is being dedicated to the identification of new metabolic 
targets, as well as uncovering the precise mechanisms of action of existing 
molecular targets for the treatment of type 2 diabetes.  
 
1.5.1 Molecular targets for the treatment of insulin resistance 
AMP-activated protein kinase (AMPK) 
 AMPK has the ability to stimulate skeletal muscle glucose uptake in an 
insulin-independent manner, making this enzyme a potential therapeutic target 
for improving glucose uptake in the face of impaired insulin signal transduction 
(see section 1.2.2).   In addition to its contribution to insulin-independent 
glucose uptake, AMPK activation has been linked to increased insulin sensitivity 
in skeletal muscle.  Fisher et al. (2002) demonstrated that activation of AMPK 
by prior treatment with AICAR resulted in increased insulin-stimulated glucose 
transport in isolated rat skeletal muscle, while Smith et al. (2005) observed 
similar effects in C2C12 myotubes (Fisher et al. 2002; Smith et al. 2005).  
However, others have observed no enhancement of insulin-stimulated glucose 
uptake in human primary myocytes that were pre-incubated with AICAR (Al-
Khalili et al. 2004).  In insulin-resistant, high-fat fed rats a single dose of AICAR 
(250 mg/kg) enhanced muscle and liver insulin sensitivity during a euglycermic-
hyperinsulinemic clamp (Iglesias et al. 2002).  Activation of AMPK via 
overexpression of LKB1 was found to inhibit serine phosphorylation of IRS-1 
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thereby enhancing insulin-stimulated Akt phosphorylation, providing a potential 
mechanism for AMPK-induced amelioration of insulin signalling (Tzatsos and 
Kandror 2006).   
 Recent work has identified the Akt substrate AS160 as a target of AMPK 
in skeletal muscle (Kramer et al. 2006; Treebak et al. 2006).  It has also been 
observed that muscle contraction can stimulate AS160 phosphorylation by an 
unknown mechanism that does not involve AMPK or Akt activation (Bruss et al. 
2005; Kramer et al. 2006).  Thus, AS160 may be a possible point of 
convergence for the insulin-dependent and –independent glucose transport 
pathways.   In addition to its acute effects on insulin signalling, chronic AMPK 
activation increases GLUT4 protein expression which may also contribute to 
amplified insulin-stimulated GLUT4 translocation (Buhl et al. 2001).   
 Aside from its role in regulating both insulin-dependent and –independent 
glucose uptake in skeletal muscle, AMPK is also a regulator of lipid metabolism.  
As depicted in figure 1.8, AMPK activation results in the upregulation of FA 
oxidation in skeletal muscle via phosphorylation of its target protein, acetyl CoA 
carboxylase (ACC), the enzyme that catalyses the rate-limiting step in the 
conversion of acetyl CoA to malonyl CoA.  AMPK-induced phosphorylation at 
ser-218 inhibits the action of ACC and results in decreased cellular malonyl 
CoA levels.  Since malonyl CoA is a potent inhibitor of CPT1, a reduction in 
malonyl CoA alleviates the inhibition of CPT1 and consequently increases the 
transfer of FA-CoA into the mitochondria for oxidation.   Fatty acid uptake and 
oxidation are thought to be mismatched in type 2 diabetes and obesity, and 
increased capacity to oxidise lipids is associated with improved insulin 
sensitivity (Bruce et al. 2003; Goodpaster et al. 2003; Perdomo et al. 2004; 
Bruce et al. 2006).   Therefore, it seems plausible that AMPK-induced increases 
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in FA oxidation may be an additional mechanism by which AMPK activation 
improves skeletal muscle insulin sensitivity. 
 
Figure 1. 8   Mechanism by which AMP-activated protein kinase (AMPK) 
stimulates fatty acid (FA) oxidation in skeletal muscle.  
Inhibitory phosphorylation of acetyl CoA carboxylase (ACC) by AMPK results in 
decreased malonyl CoA production.  This, in turn results in decreased malonyl 
CoA-mediated inhibition of carnitine palmitoyl transferase (CPT1), allowing for 
increased mitochondrial oxidation of FA-CoA. 
 
  
 Although chronic activation of AMPK in muscle would likely have 
beneficial effects to glucose and lipid metabolism, the consequences of long-
term, pharmacological systemic AMPK activation are unknown.  Chronic (7 
weeks) administration of AICAR (0.5 mg/g) reduced plasma triacylglycerol and 
free fatty acids, and increased glucose tolerance in obese Zucker rats (Buhl et 
al. 2002).  Similarly, chronic (15 wk, 3 days/week) AICAR administration in 
leptin-receptor deficient (obese Zucker rats, diabetic fatty rats) and leptin-
deficient (ob/ob mice) rodent models of insulin resistance attenuated the 
progression of hyperglycemia and diminished lipid accumulation in the liver, 
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skeletal muscle and pancreatic islets (Yu et al. 2004).  More recently, 8 weeks 
of chronic AICAR treatment improved insulin sensitivity and prevented the onset 
of type 2 diabetes in Zucker diabetic fatty (ZDF) rats (Pold et al. 2005).  
Interestingly, Pold et al. (2005) observed that exercise training (treadmill 
running) for 8 weeks produced similar improvements in the same model.  
Although the data regarding chronic AICAR treatment in animal models appears 
promising, the doses required to produce a beneficial effect (up to 1000 mg/kg) 
are believed to be too high for use in humans and would likely result in adverse 
side-effects (Winder 2000; Musi and Goodyear 2002).  Thus, the development 
of more potent pharmacological AMPK activators may be needed. 
 In summary, activation of AMPK results in 1) increased insulin-
independent glucose transport, 2) improved insulin-dependent glucose 
transport, and 3) increased FA oxidation.  All of these actions may contribute to 
improved glucose and lipid metabolism in skeletal muscle, making AMPK a 
good target for the treatment of insulin resistance. 
 
Peroxisome proliferator-activated receptor γ (PPARγ) 
 The peroxisome proliferator-activated receptors (PPARs) are ligand-
activated transcription factors that belong to the family of nuclear hormone 
receptors (Issemann and Green 1990; Rosen and Spiegelman 2001).  The 
name PPAR was derived from the initial isoform, PPARα, which was observed 
to induce proliferation of peroxisomes in the liver.  Since then, two other 
members of this transcription factor family, PPARδ and γ, have been described 
(Kliewer et al. 1994).  Because of its involvement in many critical physiological 
functions, and its potential for pharmacological regulation, PPARγ has been the 
most extensively studied isoform.  As displayed in figure 1.9, in order to initiate 
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transcription of target genes PPARs form a heterodimer with a retinoid X 
receptor (RXR) and bind to DNA at specific sequences known as PPAR 
response elements.  Further regulation of this process is mediated by the 
binding of endogenous ligands such as fatty acids, and protein-protein 
interactions with coactivators and corepressors (Forman et al. 1995; Kliewer et 
al. 1997; Spiegelman 1998; Willson et al. 2000; Rosen and Spiegelman 2001; 
Yu et al. 2005).  The presence of multiple PPARγ isoforms (PPARγ1 and 
PPARγ2) resulting from alternative promoter use and splicing may also increase 
the diversity of ligand and tissue-specific PPARγ-induced transcription (Zhu et 
al. 1995; Fajas et al. 1997). 
  
 
Figure 1. 9   Regulation of gene transcription by peroxisome proliferator-
activated receptor (PPAR)-γ.   
The transcription of target genes related to adipogenesis and lipid metabolism 
by PPARγ is regulated by several ligands, coactivators and corepressors.  The 
binding of ligands such as thiazolidinediones (TZDs) to PPARγ facilitates the 
binding of protein coactivators and impedes the binding of corepressors, which 
upregulates transcriptional activity.  RXR, retinoid X receptor; PPAR, 
peroxisome proliferator-activated receptor; PGC, PPAR gamma coactivator; 
SRC, steroid receptor coactivator; NCoR, nuclear receptor corepressor; SMRT, 
silencing mediator of retinoid and thyroid hormone receptors 
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 Although it has many physiological functions, the role that PPARγ plays 
in the regulation of lipid metabolism is of specific interest because of its 
potential involvement in the treatment of insulin resistance.  PPARγ was initially 
identified as a transcription factor important in adipose tissue differentiation and 
gene transcription (Argmann et al. 2005)   In adipocytes, PPARγ upregulates 
the transcription of genes that promote FA storage, while repressing those that 
facilitate lipolysis (Auwerx 1999).  As mentioned above, the ability of PPARγ to 
induce transcription of its target genes is partially regulated by the binding of 
endogenous ligands.  However, several high-affinity synthetic ligands have 
been generated that can pharmacologically regulate PPARγ activity.  Most 
notably the TZDs, which were developed for use as insulin-sensitisers without 
knowledge of their molecular target (Spiegelman 1998; Willson et al. 2000; 
Rosen and Spiegelman 2001), but were later discovered to be potent PPARγ 
agonists (Lehmann et al. 1995).   
 The whole-body insulin sensitising effect of TZDs and their ability to 
activate PPARγ raises the possibility that their insulin-sensitising actions may 
be attributable to altered lipid metabolism.  The potential role of PPARγ in 
insulin resistance is underscored by the fact that several epidemiological 
studies have linked allelic variations of PPARγ to obesity and type 2 diabetes 
(Argmann et al. 2005). The link between the insulin-sensitising effects of TZDs 
and their potential to alter lipid metabolism was made inadvertently in 
experiments that involved treating 3T3-L1 adipocytes or ob/ob mice with the 
TZD, pioglitazone (Kletzien et al. 1992a; Kletzien et al. 1992b).  These 
researchers noted that improved insulin sensitivity as a result of pioglitazone 
treatment occurred in concert with increased expression of adipocyte fatty acid 
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binding protein (Kletzien et al. 1992b) and enhanced adipocyte differentiation 
(Kletzien et al. 1992a).  It was concluded that the insulin-sensitising effects of 
TZDs may be attributable to their regulation of gene transcription in adipose 
tissue (Kletzien et al. 1992b). 
 Although the initial observations regarding the insulin-sensitising effects 
of PPAR agonists were observed in adipose tissue where PPARγ-1 and -2 
isoforms are expressed at high levels, these isoforms are also expressed at 
lower levels in other tissues, including skeletal muscle (Braissant et al. 1996; 
Vidal-Puig et al. 1997).  The function of PPARγ in skeletal muscle is not well-
understood. However, its expression in this tissue correlates with that of genes 
involved in the regulation of lipid metabolism such as lipoprotein lipase (LPL), 
carnitine palmitoyl transferase (CPT1) and fatty acid binding protein (FABP) 
suggesting at least permissive function as a regulator of lipid metabolism 
(Lapsys et al. 2000).  It is also believed to play a role in skeletal muscle insulin 
resistance, as gene expression of PPARγ is elevated in muscle biopsy samples 
and primary muscle cell cultures taken from obese individuals and type 2 
diabetics (Park et al. 1997).   Furthermore, PPARγ mRNA expression is acutely 
regulated by insulin and is positively correlated to body mass index (BMI) and 
fasting insulin concentration (Park et al. 1997).  In contrast, downregulation of 
PPARγ in C2C12 myocytes using antisense RNA reduced insulin sensitivity, 
whereas overexpression of PPARγ resulted in enhanced insulin-stimulated 
glucose uptake (Verma et al. 2004).  Thus, it appears that PPARγ expression in 
skeletal muscle is elevated in insulin resistant states such as obesity and type 2 
diabetes, whereas overexpression of this transcription factor results in 
increased insulin-sensitivity in cultured cells.   
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 More insight into the tissue-specific effects of PPARγ activation has been 
gained from animal models with gene deletions specific to adipose and muscle 
(Kintscher and Law 2005). Whole-body deletion of PPARγ cannot be easily 
studied, since homozygous mutation of PPARγ is lethal at an early embryonic 
stage, highlighting its importance in development (Kubota et al. 1999).  Mice 
developed with a muscle-specific deletion of PPARγ exhibit increased adiposity 
and whole-body insulin resistance (Hevener et al. 2003; Norris et al. 2003).   
Impaired glucose tolerance observed in the muscle-specific PPARγ knockout 
was at least partly attributable to the secondary development of insulin 
resistance in adipose tissue and liver (Hevener et al. 2003; Norris et al. 2003).  
However, the effect of muscle-specific PPARγ deletion on insulin sensitivity in 
this tissue is equivocal, as one study has reported a reduction (Hevener et al. 
2003), while another observed no change  in skeletal muscle insulin-stimulated 
glucose uptake (Norris et al. 2003).   With respect to muscle PPARγ knockouts, 
Norris et al. (2003) noted that reduced insulin sensitivity in adipose and liver 
was secondary to altered muscle lipid metabolism, and noted that the insulin-
sensitising effects of TZDs were normal in these mice, suggesting that muscle 
PPARγ is not required for the insulin-sensitising effects of TZDs.  In contrast, 
Hevener et al. (2003) attributed a large portion of decreased glucose tolerance 
in this same model to reduced skeletal muscle glucose uptake which was not 
ameliorated by TZD therapy, leading these workers to conclude that muscle 
PPARγ may act as a direct target for TZDs.     
 Contrary to muscle-specific knockouts, mice with an adipose-specific 
deletion of PPARγ exhibit decreased adiposity due to the role of PPARγ in 
adipogenesis, and do not display whole-body insulin-resistance (He et al. 2003; 
Koutnikova et al. 2003; Jones et al. 2005).   The relatively mild metabolic 
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consequences observed in adipose-specific PPARγ knockout mice were 
attributed to a compensatory upregulation of genes involved in the catabolism of 
FA in skeletal muscle (i.e. PPARδ, PPARγ coactivator 1 [PGC1], uncoupling 
protein 3 [UCP3]) providing an increased capacity to oxidise excess lipids 
(Koutnikova et al. 2003).  Despite normal whole-body glucose and insulin 
tolerance compared to controls, adipose tissue PPARγ knockout animals 
display hyperlipidemia and liver insulin resistance that was attributed to the 
accumulation of lipids in this tissue (He et al. 2003; Jones et al. 2005).  
Treatment with the TZD Rosiglitazone restored liver insulin sensitivity in these 
mice, suggesting that adipose PPARγ is not essential for the liver insulin-
sensitising effects of this drug (He et al. 2003).  Taken together, the results of 
these studies suggest that aside from the essential role that PPARγ plays in 
adipose tissue, the expression of this transcription factor in muscle may be 
important in the maintenance of whole-body insulin sensitivity.   
 In summary, it is likely that the interplay between aberrant glucose and 
lipid metabolism provides a functional link in the development of skeletal muscle 
insulin resistance.  The potential of AMPK and PPAR-γ to alter both of these 
metabolic pathways makes them good targets for the treatment of insulin 
resistance in skeletal muscle.  However, further study is required to elucidate 
their precise mechanisms of action. 
 
1.5.2 Rosiglitazone 
 In response to the rising prevalence of type 2 diabetes, the prescription 
and use of oral antidiabetic drugs is rapidly increasing (Wysowski et al. 2003).   
Since it was originally marketed for clinical use in the United States in 1999, the 
TZD Rosiglitazone has been widely prescribed for the treatment of type 2 
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diabetes because of its insulin-sensitising ability (Inzucchi 2002; Wysowski et al. 
2003).  In individuals with type 2 diabetes, 26 weeks of Rosiglitazone therapy 
(4-8 mg/day) improved glycemic control (as indicated by decreased 
haemoglobin A1c), and insulin sensitivity (from fasting glucose and insulin 
concentrations using the homeostasis model assessment [HOMA]) (Lebovitz et 
al. 2001).  Rosiglitazone treatment was also effective in delaying the onset of 
type 2 diabetes in individuals with insulin resistance and impaired glucose 
tolerance (Durbin 2004).  
 
Figure 1. 10 Chemical structure of Rosiglitazone.  
The peroxisome proliferator-activated receptor agonist Rosiglitazone is a widely 
used insulin-sensitising agent with the ability to alter lipid and glucose 
metabolism. 
 
 As a TZD, Rosiglitazone is also a PPARγ agonist and displays a higher 
affinity for PPARγ than other members of this family (i.e.troglitazone and 
pioglitazone), allowing it to be effective at lower doses (Young et al. 1998).  
Consequently, Rosiglitazone has the ability to alter lipid metabolism in addition 
to its insulin-sensitising effects.  In this regard, improved insulin sensitivity 
following 12 weeks of Rosiglitazone treatment (8 mg/day) has been associated 
with increased body weight and fat mass but decreased plasma non-esterified 
fatty acid (NEFA) concentration and turnover in individuals with type 2 diabetes 
(Miyazaki et al. 2001).  The improved plasma lipid status attributed to TZD 
therapy is likely due to decreased hepatic TAG production and increased TAG 
clearance combined with enhanced insulin-induced suppression of lipolysis 
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(Oakes et al. 2001).  Increased adiposity associated with Rosiglitazone 
treatment is well-documented, with the increased fat deposition appearing in 
subcutaneous, rather than visceral compartments (Carey et al. 2002).   
 Improved insulin sensitivity in the face of increased adiposity seems 
paradoxical given the strong relationship between obesity and insulin 
resistance.  This apparent contradiction has generated great interest in the 
mechanism by which Rosiglitazone mediates its insulin sensitising actions.  
However, despite extensive study, the precise mode of action of this agent 
remains unknown.  The “lipid steal hypothesis” of TZD action suggests that 
PPARγ agonists may prevent lipid-induced insulin resistance by upregulating 
FA uptake and storage in adipose tissue, thereby reducing plasma lipids and 
preventing excessive ectopic lipid deposition in other insulin sensitive tissues 
such as liver and skeletal muscle (Hockings et al. 2003; Jucker et al. 2003; Ye 
et al. 2004).  The sequestration of FA into adipose tissue would have the effect 
of sparing other tissues from lipotoxicity, thereby allowing them to maintain their 
normal roles in maintaining glucose homeostasis.  Early support for this 
hypothesis came from work demonstrating that in addition to improving plasma 
lipid availability, Rosiglitazone treatment (10 µmol/kg/day for 4 days) 
significantly reduced liver triglyceride content in high-fat-fed rats (Oakes et al. 
1994).  More direct evidence came from the observation that treating healthy 
rats with Rosiglitazone (4 mg/kg) for 7 days resulted in increased adipose tissue 
lipid uptake and, consequently reduced liver and muscle FA uptake during 
acute lipid infusion (Ye et al. 2004).   Thus, it is apparent that Rosiglitazone 
treatment has the potential to improve whole-body glucose and lipid 
metabolism.  Since skeletal muscle lipid accumulation is thought to be a major 
contributing factor to whole-body insulin-resistance, it is possible that the 
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insulin-sensitising effects of Rosiglitazone are, at least in part, attributable to the 
prevention of lipid accumulation in this tissue.  However, it is currently unclear 
whether the insulin-sensitising effects of long-term Rosiglitazone treatment are 
directly attributable to insulin-sensitisation in skeletal muscle secondary to 
reduced lipid accumulation.      
 The effect of Rosiglitazone treatment on skeletal muscle lipid storage is 
equivocal, as previous investigations have reported a decrease (Hockings et al. 
2003; Jucker et al. 2003; Ye et al. 2003), an increase (Muurling et al. 2003; 
Todd et al. 2006), or no effect (Oakes et al. 1994; Oakes et al. 1997b; 
Mayerson et al. 2002; Coort et al. 2005) on muscle TAG content.  Regardless of 
its effect on skeletal muscle lipid storage, all of these studies demonstrated 
whole-body insulin-sensitisation in response to Rosiglitazone treatment, 
indicating that reduction of muscle lipid storage may not be its primary mode of 
action.  In support of this contention, Muurling et al. (2003) reported that 
treatment of ob/ob mice with Rosiglitazone (3 mg/kg/day) for 10 weeks resulted 
in improved skeletal muscle 2-deoxyglucose uptake during a hyperinsulinemic-
euglycemic clamp, despite an increase in skeletal muscle TAG content.  It is 
important to note that the use of a chemical extraction method to measure 
muscle TAG content in Muurling et al. (2003), can not distinguish between 
intramyocellular (IMCL) and extramyocellular (EMCL) lipid content.  However, 
when determined by 1H-nuclear magnetic resonance spectroscopy (NMR), a 
technique that can distinguish between these two lipid pools, EMCL was shown 
to increase following 3 months of Rosiglitazone treatment (8 mg/kg/day), while 
IMCL did not change in the muscle of individuals with type 2 diabetes 
(Mayerson et al. 2002).  Furthermore, in the study of Mayerson et al. (2002) 
insulin sensitivity was improved by Rosiglitazone treatment and was associated 
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with a decrease in liver TAG content, suggesting that “lipid steal” from liver may 
be more important than reduced muscle lipid accumulation in Rosiglitazone-
induced insulin sensitisation.  It is also possible that in the face of increased or 
unchanged total muscle TAG content, there is a decrease in those lipid species 
that have been linked to impairments in insulin sensitivity such as FA-CoA, 
ceramide and DAG.  Further work is needed to determine whether 
Rosiglitazone treatment results in changes in lipid species other than TAG. 
 Although it seems likely that Rosiglitazone’s insulin-sensitising effects 
are at least partly attributable to PPARγ activation, it is also possible that it acts 
via PPAR-independent mechanisms (Feinstein et al. 2005).   Treatment of H-
2Kb skeletal muscle cells with Rosiglitazone resulted in stimulation of both the 
AMPK-α1 and –α2 isoforms via the AMP/ATP-dependent pathway (Fryer et al. 
2002).  The timeframe of this response (<30 min) was believed to be too short 
to elicit PPARγ-dependent changes in gene transcription, leading the authors to 
conclude that activation of AMPK may play a role in Rosiglitazone’s insulin-
sensitising action.  It remains unclear whether Rosiglitazone’s insulin-sensitising 
effects in vivo are attributable to skeletal muscle AMPK activation. 
 Due to its relatively recent release as a therapy for insulin resistance, the 
long-term consequences of Rosiglitazone treatment are unknown. However, 
several adverse side-effects have been associated with the use of this drug 
including increased adiposity, oedema and increased low-density lipoprotein 
cholesterol (Malinowski and Bolesta 2000).  The first TZD approved for the 
treatment of insulin-resistance, Troglitazone, was removed from the market due 
to concerns regarding its potential to induce hepatotoxicity (Malinowski and 
Bolesta 2000).  Clarification of the mechanisms by which chronic Rosiglitazone 
treatment exerts its insulin-sensitising effects may provide insight for the 
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development of new, more specific treatments for insulin resistance that 
produce fewer adverse side-effects.   
1.5.3 Exercise Training 
 The limited effectiveness and adverse side-effects associated with 
current oral antihyperglycemic agents has prompted a search for new drug 
targets for the treatment of type 2 diabetes (Moller 2001).  However, since 
lifestyle factors leading to obesity appear to be major contributors to the 
increased world-wide prevalence of type 2 diabetes, it follows that lifestyle 
modification may be prescribed as an effective therapy for this disease (Moller 
2001).  Indeed, lifestyle modification through increased physical activity and 
dietary control has been demonstrated as a successful means for the 
prevention of type 2 diabetes in individuals with impaired glucose tolerance 
(Pan et al. 1997b; Eriksson et al. 1999; Tuomilehto et al. 2001; Molitch et al. 
2003).  In a randomised, placebo controlled trial of >3000 individuals with 
impaired glucose tolerance, lifestyle intervention (reduced caloric intake 
combined with 150 min of moderate physical exercise per week)  was ~two-fold 
more effective in reducing the incidence of type 2 diabetes  than metformin  
treatment (850 mg twice daily) over a period of ~2.8 years (Knowler et al. 2002).  
Although these investigations (Pan et al. 1997b; Eriksson et al. 1999; 
Tuomilehto et al. 2001; Knowler et al. 2002; Molitch et al. 2003) studied a 
combination of lifestyle adjustments that may have contributed reduced 
incidence of type 2 diabetes, there is convincing evidence to support the 
prescription of exercise as a therapy for insulin resistance and type 2 diabetes 
(Booth et al. 2000; Booth et al. 2002; Hawley 2004; Pedersen and Saltin 2006).   
In this regard, Houmard et al. (2004) demonstrated a “dose-response” 
relationship between volume of exercise training (min/week) and insulin 
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sensitivity in sedentary, obese and overweight individuals that were randomly 
assigned to exercise programs of varying volumes and intensities for 6 months 
(Houmard et al. 2004).  These workers concluded that an exercise prescription 
of 170 min of walking or jogging per week was more effective than 115 min for 
improving whole-body insulin sensitivity, regardless of exercise intensity, 
although both volumes of exercise improved insulin sensitivity compared to 
sedentary controls (Houmard et al. 2004).  
 The observation that exercise training increases both insulin-dependent 
and -independent glucose transport in skeletal muscle is well-established 
(Holloszy and Narahara 1965; Richter et al. 1982; Ivy et al. 1983; Garetto et al. 
1984; Richter et al. 1984; Wallberg-Henriksson et al. 1988; Holloszy 2005).   
Similar observations regarding exercise-induced improvements in skeletal 
muscle glucose transport have been made in insulin-resistant rats (Cortez et al. 
1991), diabetic rats (Wallberg-Henriksson and Holloszy 1984) and humans with 
insulin resistance and type 2 diabetes (Christ-Roberts et al. 2003).  Acutely, 
increased glucose transport in response to a bout of exercise or muscle 
contraction may be mediated by a variety of intramyocellular signalling events 
including AMPK activation, Akt phosphorylation, nitric oxide production,  and 
calcium-mediated mechanisms involving Ca2+/calmodulin-dependent protein 
kinase (CaMK) and PKC (Sakamoto and Goodyear 2002; Hawley 2004; Richter 
et al. 2004; Jessen and Goodyear 2005).  However, the insulin-sensitising 
effects of an acute exercise bout are short-lived, and may only persist for up to 
48 hours if another bout of exercise is not undertaken (Ivy et al. 1983; Etgen et 
al. 1993).  In contrast, chronic exercise training may produce metabolic 
adaptations that result in sustained improvements in whole-body and muscle 
insulin sensitivity (Booth et al. 2000; Booth et al. 2002; Hawley 2004; Pedersen 
 43
and Saltin 2006). The remainder of this review will focus on the chronic 
adaptations in skeletal muscle that may result in improved insulin sensitivity 
following chronic exercise training.  A summary of these improvements is shown 
in Figure 1.11. 
    
Figure 1. 11 Chronic adaptations that may contribute to exercise training-
induced improvements in skeletal muscle insulin sensitivity.  
AMPK, AMP-activated protein kinase; HK, hexokinase; CS, citrate synthase; 
GLUT, glucose transporter; PI3K, phosphatidylinositol-3-kinase; AS160, Akt 
substrate of 160 kDa; NRF, nuclear respiratory factor; PPAR, peroxisome 
proliferator-activated receptor; PGC, PPARγ Coactivator; DAG, diacylglycerol 
  
 Exercise-induced increases in muscle insulin sensitivity may be 
attributed to increased expression and/or activity of signalling proteins involved 
in the regulation of skeletal muscle glucose uptake (Zierath 2002).  Perhaps the 
most consistently observed effect of exercise training in healthy and insulin 
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resistant skeletal muscle is increased expression of GLUT4 protein (Henriksen 
2002; Zierath 2002; Holloszy 2005). In addition, insulin sensitivity following 7 
days of exercise training in previously sedentary men was associated with 
increased insulin-stimulated PI-3 kinase activity (Houmard et al. 1999).  
However, the mechanism for this increase is unknown, as it was not 
accompanied by increased protein levels of PI-3 kinase or upstream 
components of the insulin-signalling cascade. 
 The upregulation of AMPK is another potential mechanism by which 
exercise training improves insulin sensitivity.   In addition to acute activation of 
AMPK due to muscle contraction (see section 1.2.2), chronic exercise training 
may result in an upregulation of AMPK protein.   In healthy individuals, 3 weeks 
of endurance training increased the skeletal muscle protein content of the 
AMPK α1, β2 and γ1 subunits (Frosig et al. 2004).  Similarly, 7 weeks of 
exercise training (treadmill running) in obese Zucker rats resulted in a 1.5-fold 
increase in AMPKα1 protein expression and restored impaired AMPK activation 
to the level of lean controls (Sriwijitkamol et al. 2006).  Pold et al (2005) 
observed that 8 weeks of treadmill running in ZDF rats produced similar 
improvements in insulin sensitivity as daily AICAR adiminstration.  However, 
unlike leptin-deficient (ob/ob mouse) and leptin receptor-deficient (fa/fa Zucker 
rat) rodent models of diabetes (Yu et al. 2004), humans with type 2 diabetes do 
not exhibit decreased AMPK subunit expression or activation compared to 
healthy controls (Wojtaszewski et al. 2005).  Even so, Wojtaszewski et al. 
(2005) observed a comparable increase in the expression of the α1, β2 and γ3 
subunits of AMPK in response to 6 weeks of resistance training in type 2 
diabetic individuals and healthy controls (Wojtaszewski et al. 2005).  
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 It has been established that exercise training induces a chronic 
upregulation of AMPK (Frosig et al. 2004; Wojtaszewski et al. 2005; 
Sriwijitkamol et al. 2006).  Furthermore, it has been previously described that 
chronic activation of AMPK through AICAR results in improved skeletal muscle 
insulin sensitivity (see section 1.5.1).  Thus, it is plausible that the insulin-
sensitising effects of exercise training are at least partially attributable to 
increased skeletal muscle AMPK activation.  Chronic AMPK activation, as seen 
with exercise training, may act to improve insulin sensitivity by regulating the 
expression of specific genes involved in glucose and lipid homeostasis 
(Jorgensen et al. 2006).  AMPK activation through daily AICAR injections (1 
mg/g) for 4 weeks was associated with increased expression of GLUT4, 
hexokinase II (HKII) and mitochondrial proteins (i.e. citrate synthase, 
cytochrome C) in rodent skeletal muscle (Winder et al. 2000; Zheng et al. 
2001).  It is also possible that exercise-induced upregulation of AMPK mediates 
its effects through distal components of the insulin signalling cascade.   
Recenty, AICAR was shown to induce AS160 phosphorlyation in mouse 
skeletal muscle, by a mechanism that was independent of insulin, but at least 
partly attributable to the AMPKα2 isoform (Bruss et al. 2005; Kramer et al. 2006; 
Treebak et al. 2006).  Interestingly, it was also observed that muscle contraction 
stimulated AS160 phosphorylation by an unknown mechanism that did not 
involve AMPK or Akt activation (Bruss et al. 2005; Kramer et al. 2006). The 
effects of chronic exercise training on AS160 expression and phosphorylation 
are currently unknown. 
 The regulation of lipid turnover and utilisation is another potential 
mechanism by which exercise training may improve insulin sensitivity (Bruce 
and Hawley 2004).   Exercise training results in an increase in the oxidative 
 46
capacity of skeletal muscle by upregulating the expression of proteins involved 
in mitochondrial biogenesis such as PGC1, PPARα and nuclear respiratory 
factor 1 (NRF1) (Gollnick and Saltin 1982; Irrcher et al. 2003).  Oxidative 
enzyme capacity is low in individuals with insulin resistance, which is thought 
contribute to a “metabolic inflexibility” that does not allow for easy transition 
between fasting and postprandial states (Kelley 2002).  This inflexibility, in turn 
is thought to contribute to the aberrant skeletal muscle glucose and lipid 
metabolism that is associated with insulin resistance and type 2 diabetes.  
Furthermore, the maximal activities of several skeletal muscle oxidative 
enzymes (i.e. citrate synthase) are good predictors of whole-body insulin 
sensitivity, suggesting that treatments that increase oxidative capacity may also 
improve insulin sensitivity (Bruce et al. 2003).  In support of this contention, 
Goodpaster et al. (2003) demonstrated that the strongest predictor of insulin 
sensitivity following endurance training in obese individuals was enhanced lipid 
oxidation (Goodpaster et al. 2003).  Furthermore, increased oxidative capacity 
following exercise training was recently associated with increased CPT1 activity 
and decreased ceramide and DAG content in the muscle of obese individuals 
(Bruce et al. 2006).  The findings by Bruce et al. (2006) suggest that exercise 
training may improve muscle insulin sensitivity by increasing the proportion of 
lipids targeted for oxidation, thereby reducing the accumulation of lipid species 
that are known to inhibit insulin signal transduction.   
 Although there appears to be a strong association between improved 
muscle oxidative capacity and whole-body insulin sensitivity, this relationship 
may be dependent on age.  A cross-sectional study examining individuals aged 
between 22-87 years, found that although oxidative capacity increased to a 
similar degree following 16 weeks of aerobic training in all age groups, this was 
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not associated with an increase in insulin sensitivity in individuals over 60 years 
of age (Short et al. 2003).  Similar results were obtained by Pruchnic et al. 
(2004) who observed an increase in oxidative capacity following 12 weeks of 
exercise training, but only a trend (P=0.14) toward increased insulin sensitivity 
in older individuals (67.3 ± 0.7 years) (Pruchnic et al. 2004).  The observations 
of Short et al. (2003) and Pruchnic et al. (2004) suggest that insulin resistance 
associated with obesity and type 2 diabetes may involve different mechanisms 
than age-induced insulin resistance.  
 In summary, there are several ways in which exercise training may 
improve skeletal muscle glucose uptake.  These include upregulation of GLUT4 
expression, chronic activation of AMPK, facilitation of insulin signal transduction 
at the level of PI3-kinase and AS160, as well as increases in the expression of 
several proteins involved in glucose and lipid utilisation and turnover.  
Furthermore, exercise training has the potential to ameliorate several other 
conditions associated with the metabolic syndrome, including obesity, 
hypertension and cardiovascular disease, and is not associated with adverse 
metabolic side-effects (Roberts and Barnard 2005; Pedersen and Saltin 2006).  
Therefore, exercise training is an effective therapy for the treatment of insulin-
resistance in skeletal muscle. 
 Given the potential for Rosiglitazone and exercise training to improve 
insulin sensitivity by different mechanisms, it is plausible that their combined 
treatment would produce additive beneficial effects.  In support of this 
contention, Hevener et al., (2000) observed that treating obese Zucker (fa/fa) 
rats with the TZD Troglitazone combined with exercise training (treadmill 
running) for 3 weeks was more effective in improving insulin sensitivity than 
either treatment alone (Hevener et al. 2000).  Troglitazone and exercise training 
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produced an additive increase in skeletal muscle GLUT4 content, suggesting 
that the whole-body insulin sensitisation was at least partially attributable to 
increased muscle glucose uptake (Hevener et al. 2000).  More investigation into 
the individual and combined effects of exercise and TZD therapy may provide 
insight into the respective mechanisms of action of these therapies. 
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CHAPTER TWO:  Aims of thesis 
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 The review of literature (chapter one) highlighted the stong association 
between aberrant skeletal muscle lipid metabolism and whole-body insulin-
sensitivity. However, it was also noted that some important research questions 
remained unanswered.  Specifically, little is known about the efficacy by which 
current treatments for insulin resistance improve glucose and lipid metabolism 
in skeletal muscle.  Accordingly, the primary aim of the invesitgations 
undertaken for this thesis was to enhance our understanding of the 
mechanisms by which two common therapies for the treatment of insulin 
resistance, Rosiglitazone and exercise training, reverse aberrant lipid handling 
and improve insulin sensitivity in this tissue.  
 The objective of the initial investigation which is described in chapter 
three, was to determine the changes to skeletal muscle lipid metabolism that 
occur as a result of chronic Rosiglitazone treatment in a genetic model of insulin 
resistance, the obese Zucker rat.  It was hypothesised that increased 
intramuscular lipid storage would be associated with impaired glucose tolerance 
in the obese Zucker rat relative to lean control animals, and that Rosiglitazone 
treatment would improve glucose tolerance and reduce muscle lipid content.   
 The subsequent investigation (chapter four) examined an alternative and 
PPARγ-independent mechanism by which Rosiglitazone may improve insulin 
sensitivity in the same animal model.  It was hypothesised that AMPK activity 
would be increased by chronic Rosiglitazone treatment, providing an alternative 
mechanism for Rosiglitazone’s insulin-sensitising actions in muscle. 
 The final study described in chapter five compared the independent and 
interactive effects of Rosiglitazone treatment and exercise training on muscle 
glucose and lipid metabolism in a less severe model of insulin resistance, the 
fat-fed rat.  Given that both treatments have the potential to improve skeletal 
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muscle insulin sensitivity; it was hypothesised that the combination of exercise 
and Rosiglitazone treatment would result in additive improvements in insulin-
stimulated muscle glucose transport.  Furthermore, it was hypothesised that 
changes in insulin-stimulated glucose transport following exercise training or 
Rosiglitazone treatment would be associated with changes in fatty acid 
transport and storage. 
 It is hoped that information gathered from experiments undertaken for 
this thesis will enhance our understanding of the mechanisms by which these 
common therapies for insulin resistance improve skeletal muscle insulin 
sensitivity.    Continued discovery of the factors that lead to skeletal muscle 
insulin resistance, and the mechanisms by which available insulin-sensitising 
agents act to overcome these impairments may lead to the development of 
more effective treatments for this disease in the future.
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CHAPTER THREE:  Rosiglitazone Enhances Glucose 
Tolerance by Mechanisms Other Than Reduction of 
Fatty Acid Accumulation within Skeletal Muscle 
 
 
 
 
Adapted from: Lessard SJ, LoGiudice SL, Lau W, Reid JJ, Turner N, Febbraio 
MA, Hawley JA, Watt MJ.  (2004)  Endocrinology 145: 5565-5570. 
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3.1 Introduction 
 Insulin resistance in skeletal muscle is a characteristic feature of obesity, 
and precedes the development of type 2 diabetes and its secondary 
complications (DeFronzo 1992).  The direct cause of skeletal muscle insulin 
resistance in obese individuals remains unclear; however, accumulation of 
intramuscular triacylglycerol (IMTG) is strongly associated with both whole-body 
and skeletal muscle insulin resistance (Pan et al. 1997a; Kelley et al. 2002; 
Krssak and Roden 2004).  The molecular mechanisms linking IMTG 
accumulation and impaired insulin sensitivity have not been fully elucidated, but 
it has been proposed that IMTG acts as a marker for the presence of other, 
more metabolically active lipid intermediates, which are directly linked to defects 
in insulin signalling, and may play a causative role in obesity-induced insulin 
resistance (Shulman 2000). 
 One such lipid intermediate is diacylglycerol, which is elevated in both 
genetic and diet-induced insulin resistance (Kim et al. 2001; Itani et al. 2002; Yu 
et al. 2002).  Diacylglycerol is proposed to induce insulin resistance by 
activating diacylglycerol-sensitive protein kinase C (PKC) isoforms (Schmitz-
Peiffer et al. 1997; Qu et al. 1999; Montell et al. 2001), which results in serine 
phosphorylation of insulin receptor substrate (IRS)-1  (Cortright et al. 2000; Lin 
et al. 2001). Ceramide, which is a second messenger in the sphingomyelin 
signalling pathway, is also elevated in the muscle of obese, insulin resistant 
humans (Adams et al. 2004; Straczkowski et al. 2004), and rodents (Turinsky et 
al. 1990), and its accumulation affects downstream insulin signalling by 
preventing insulin-induced Akt phosphorylation and activation (Schmitz-Peiffer 
et al. 1999; Chavez et al. 2003). 
 54
 Rosiglitazone belongs to a class of insulin sensitizing drugs that are 
ligands for peroxisome proliferator activated receptor gamma (PPAR-γ).  PPAR-
γ is a critical transcription factor that influences numerous genes related to lipid 
homeostasis, suggesting that changes in lipid metabolism may mediate the 
therapeutic effects of Rosiglitazone. In addition to improving insulin sensitivity, 
chronic Rosiglitazone treatment results in decreased blood triglyceride (Jucker 
et al. 2003; Muurling et al. 2003), and free fatty acid (FA) levels (Miyazaki et al. 
2003; Buse et al. 2004), and increased FA uptake and oxidation in cultured 
skeletal muscle (Wilmsen et al. 2003). Since there is strong evidence for the 
role of several lipid species in the development of skeletal muscle insulin 
resistance, and PPAR-γ agonism results in altered lipid homeostasis, the 
primary aim of the current investigation was to determine the effects of 
Rosiglitazone on the skeletal muscle lipid profile.  
 In this regard, previous studies examining IMTG content following 
chronic Rosiglitazone treatment have reported increased (Muurling et al. 2003), 
decreased (Hockings et al. 2003; Kim et al. 2003a; Kuhlmann et al. 2003), and 
unchanged (Mayerson et al. 2002; Kuhlmann et al. 2003) levels.  The changes 
observed in IMTG content with Rosiglitazone treatment may result from 
alterations in regulatory enzymes of lipid turnover such as hormone sensitive 
lipase (HSL) and glycerol 3-phosphate acyltransferase (GPAT).  However, the 
effect of Rosiglitazone treatment on the protein content and activities of these 
regulatory enzymes are unresolved. 
 The present investigation examined the effect of chronic Rosiglitazone 
treatment on both glucose tolerance, the skeletal muscle content of lipid 
metabolites and the activities of lipid regulatory enzymes in a rodent model of 
insulin resistance.  It was hypothesized that muscle lipids would be elevated in 
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obesity, and that improved glucose tolerance following Rosiglitazone treatment 
would coincide with decreased levels of IMTG, diacylglycerol and ceramide. 
 
3.2 Materials and Methods
Animals 
 Female obese Zucker (fa/fa) and age-matched lean (fa/?) rats were 
obtained from Monash Animal Services (Victoria, Australia) at 19 wk of age.  
Rats were housed under controlled light (12:12 light:dark) at an ambient 
temperature of 21oC. Animals had free access to standard rat chow and water 
except when overnight fasting was required for blood measurements.  All 
procedures were approved by the RMIT University Animal Ethics Committee. 
The obese rats were randomly divided into two experimental groups: control 
(OB CON, n=9) and Rosiglitazone (OB RSG, n=9).  The lean rats were treated 
with vehicle (LN CON, n=9) and acted as a control group for OB CON. Rats 
were dosed daily, for 6 wk, by oral gavage with either vehicle, which consisted 
of 0.5% carboxymethylcellulose (CMC; Sigma-Aldrich, Inc., MO, USA) (100 
µL/100 g body mass), or 3 mg/kg Rosiglitazone (GlaxoSmith Kline, UK) 
suspended in an equal volume of CMC.   
Oral glucose tolerance test (OGTT) and Surgery 
 Following the 6 wk experimental period, rats were overnight fasted, 
weighed and underwent an OGTT. To assess oral glucose tolerance, glucose 
(70% w/v solution) was administered by oral gavage at a dose of 2.5 g/kg body 
weight, and tail blood was obtained at time -1, 10, 15, 30, 60 and 90 min after 
administration of the glucose load. Three days later, rats were euthanized by 
CO2 asphyxia, followed by exsanguination.  The soleus and red gastrocnemius 
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muscles were rapidly dissected from the rat hindlimbs, snap- frozen in liquid 
nitrogen and stored at –80°C for later analysis. 
Blood Metabolite Measurements.  
 Blood was analysed for fasting concentrations of glucose, insulin, 
triglyceride and cholesterol.  Plasma was obtained by centrifugation of whole 
blood collected at the time of euthanasia, and stored at –80°C until analysis.  
Blood glucose levels were monitored with the MediSense2™ Blood Glucose 
Testing System (MediSense Australia Pty. Ltd, Victoria, Australia).  Plasma 
insulin levels were determined using an enzyme immunoassay kit 
(Ultrasensitive Rat Insulin ELISA, Mercodia AB, Uppsala, Sweden) and plasma 
triglycerides and total cholesterol were measured using the enzymatic assay 
kits GPO-PAP and CHOD-PAP (Roche, Basel, Switzerland), respectively. 
Analysis of intramuscular muscle lipids 
 IMTG content was analysed as previously described (Frayn and 
Maycock 1980).  Freeze-dried muscle was powdered, and cleaned of all visible 
connective tissue and blood under magnification.  Lipid was extracted by a 
Folch extraction (Folch et al. 1957), the triacylglycerol was saponified in an 
ethanol / KOH solution (Sigma-Aldrich, Inc., MO, USA) at 60oC, and glycerol 
content was determined fluorometrically.  
 The fatty acid composition of muscle triacylglycerols was determined on 
a separate portion of powdered skeletal muscle. Skeletal muscle lipids were 
extracted (Folch et al. 1957) and triacylglycerols were separated from 
phospholipids by solid phase extraction on Sep-Pak® Silica cartridges 
(Waters™ Division, Millipore Corporation, MA, USA) as described previously 
(Pan and Storlien 1993). Triacylglycerol fractions were transmethylated with 
14% (w/v) boron trifluoride in methanol and fatty acid methyl esters were 
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separated by gas-liquid chromatography on a Hewlett-Packard 5890 Series II 
gas chromatograph (Hewlett-Packard, Palo Alto, CA, USA) with a fused silica 
capillary column. Individual fatty acids were identified by comparing each peak’s 
retention time to those of external standards, and are expressed as the mole 
percentage of total fatty acids. The five major fatty acids in the triacylglycerol 
pool (16:0, 16:1, 18:0, 18:1, 18:2), which represent ~95% of total muscle fatty 
acids are presented.  
 Diacylglycerol and ceramide were extracted and quantified according to 
the methods of Preiss et al. (Preiss et al. 1986).  Briefly, lipids were extracted 
from freeze-dried, powdered soleus muscle using chloroform: methanol: PBS+ 
0.2% SDS (1:2:0.8).  Diacylglycerol kinase and [γ-32P] ATP (Amersham 
Biosciences, NSW, Australia; 15 µCi/µmol cold ATP) were added to extracts, 
and the reaction was stopped using chloroform:methanol (2:1; Sigma-Aldrich, 
Inc., MO, USA).  Samples were spotted onto thin-layer chromatography plates 
and developed to two thirds of the total plate length. Bands corresponding to 
diacylglycerol and ceramide were identified against standards after phospho-
imaging, dried, scraped from the TLC plate and counted in a liquid scintillation 
analyser (Tri-Carb 2500TR, Packard, Canberra, Australia). 
Analysis of hormone-sensitive lipase (HSL) activity 
 An aliquot of freeze-dried muscle was used to determine HSL activity as 
described previously (Watt et al. 2003). Briefly, the powdered muscle was 
homogenized and after centrifugation the supernatant was removed and 
analysed for HSL activity against a triolein substrate. All measurements were 
made in triplicate and the mean of these values is reported.  
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Analysis of glycerol 3 phospate acyltransferase (GPAT) activity 
 Skeletal muscle GPAT activity was determined as described by Muoio et 
al., (Muoio et al. 1999). After homogenisation, total GPAT activity was 
measured with 900 mM [3H] glycerol-3-phosphate (ARC, St. Louis, USA) and 90 
mM palmitoyl CoA. The reaction was run for 20 min at 37oC and stopped with 
1% HClO4 (Sigma-Aldrich, Inc., MO, USA) and chloroform : methanol (2:1; 
Sigma-Aldrich, Inc., MO, USA). After a series of washes with HClO4, 1 mL of 
the organic phase containing the labeled G-3-P incorporated into 
lysophospatidic acid was dried and 4 mL scintillation fluid was added. 
Radioactivity was determined with a liquid scintillation analyser. 
Subcellular fractionation and Western blotting protocol 
 Soleus muscle was homogenized in 8x wt/vol ice cold buffer containing 
20 mM HEPES (pH 7.4), 2 mM EGTA, 50mM β-glycerophosphate, 1 mM DTT, 
1 mM Na3VO4, 10% glycerol, 3 mM benzamidine, 10 µM leupeptin, 5 µM 
pepstatin-A and 1mM PMSF (all from Sigma-Aldrich Inc, MO, USA).  The 
homogenate was centrifuged at 100,000 g for 30 min at 4°C, and the 
supernatant was collected as the cytosolic fraction.  The pellet was 
resuspended by agitation in 4x wt/vol of ice-cold homogenisation buffer to which 
1% Triton-X (Sigma-Aldrich Inc., MO, USA) was added.  The resuspended 
pellet was then centrifuged at 15,000 g for 10 min at 4°C.  The supernatant, 
representing the total membrane fraction, was collected.  Both the membrane 
and cytosolic fractions were stored at –80°C. A separate portion of soleus 
muscle was homogenized, centrifuged at 16,000 g for 60 min and later 
analysed for total cellular HSL protein.  
 Protein concentration of the muscle lysates was determined (Pierce, 
Rockford, IL, USA). Muscle lysates (100 µg) from both fractions were solubilized 
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in Laemelli buffer and separated by SDS-PAGE.  Proteins were transferred to a 
nitrocellulose membrane (BioRad Laboratories, CA, USA) by electrophoresis, 
and the membranes were blocked, and incubated overnight at 4°C with 
antibodies specific for HSL (kindly provided by Fredric Kraemer, Stanford 
University, CA, USA) or for PKC-θ, -α/β, or -δ isoforms (1:1000; Cell Signaling, 
Beverley, MA, USA).  The immunoreactive proteins were detected with 
enhanced chemiluminescence (Perkin Elmer, Rowville, Victoria, Australia) and 
quantified by densitometry. 
3.2.1 Statistical Analysis 
 Results are presented as means ± standard error (SE).  All statistical 
analyses were performed using the unpaired Student’s t-test.  A P value of less 
than 0.05 was considered significant. 
3.3 Results 
 Obese control rats at 25 wk of age had a greater body mass and 
elevated fasting plasma insulin, triglyceride, and cholesterol levels compared 
with lean control rats (Table 3.1, P<0.05).  Rosiglitazone treatment in obese rats 
resulted in further increases in body mass and plasma cholesterol, but lower 
plasma insulin and triglyceride levels compared with OB CON (Table 3.1, 
P<0.05).  Compared with lean rats, obese rats had elevated (P<0.05) plasma 
glucose levels throughout the oral glucose challenge (Figure 3.1). The area 
under the curve (AUC) during the oral glucose challenge averaged 123 ± 3 and 
152 ± 8 mM for lean and obese control rats (P<0.05), respectively. 
Rosiglitazone treatment improved glucose tolerance in obese rats, as indicated 
by a reduced AUC (126 ± 4 mM, P<0.05; Figure 3.1). 
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Table 3. 1 Body mass and plasma characteristics of from lean (LN 
CON), obese (OB CON) and rats treated with Rosiglitazone (OB RSG).  
 LN CON OB CON OB RSG 
Mass (g) 211 ± 7.6 388 ± 9.4* 444 ± 13.3# 
Plasma    
Glucose (mM) 6.3 ± 0.5 7.1 ± 0.5 6.4 ± 0.3 
Insulin (pM) 62 ± 18 986 ± 291* 103 ± 49# 
Triglyceride (mM) 0.42 ± 0.07 2.93 ± 0.64* 1.15 ± 0.19# 
Cholesterol (mM) 1.13 ± 0.06 1.57 ± 0.05* 1.84 ± 0.11# 
    
LN CON vs OB CON, P<0.05; # OB CON vs OB RSG, P<0.05; n=9/group. 
 
 
 
 
Figure 3. 1 Oral glucose tolerance test.  
Glucose was administered by oral gavage at a dose of 2.5 g/kg body weight, 
and blood glucose was measured for 90 min. P < 0.01, OB CON vs. OB RSG 
(n=9/group). 
 
 
 IMTG content in soleus muscle was higher in obese compared with lean 
rats (70.5 ± 5.1 vs 27.5 ± 2.0 µmol/g dm, P<0.001), and increased a further 
30% (P=0.04) following Rosiglitazone treatment (Figure 3.2).  Soleus muscle 
diacylglycerol and ceramide levels were not elevated when comparing lean with 
obese control rats, but were increased by 65% (P<0.001) and 100% (P=0.02), 
respectively, following Rosiglitazone treatment (Figure 3.2).  IMTG content in a 
glycolytic muscle, the extensor digitorum longus (EDL), was also increased with 
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obesity (LN CON: 9.3 ± 2.4 vs OB CON: 35.2 ± 8.4, P<0.05), but was not 
increased following Rosiglitazone treatment.  
 
 
 
Figure 3. 2 Intramyocellular lipids.  
Changes in skeletal muscle IMTG (A), diacylglycerol (B), and ceramide (C) with 
obesity (LN CON vs. OB CON), and RSG treatment (OB CON vs. OB RSG). 
Significant differences (P < 0.05; n=9/group) between groups are indicated by 
the P values listed on the figure. 
 
 In order to determine the potential mechanism(s) mediating the changes 
in intramuscular IMTG and diacylglycerol levels with Rosiglitazone treatment, 
the basal activities of HSL and GPAT were assessed.  There was no difference 
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in HSL activity between lean and obese control rats; whereas HSL activity was 
decreased by ~30% following Rosiglitazone treatment in obese rats (Figure 3.3 
A, P=0.02).  The decreased HSL activity in OB RSG was not associated with 
changes in total HSL protein as determined by Western blot analysis (Figure 3.3 
B and C).  Skeletal muscle GPAT activity was not altered by obesity, or 
Rosiglitazone treatment (Figure 3.3 D).  
 
 
Figure 3. 3 Activity and protein levels of lipid regulatory enzymes.  
A) HSL activity with obesity (LN CON vs. OB CON, not significant) and RSG 
treatment (OB CON vs. OB RSG, P = 0.02). B) A representative Western blot of 
total HSL protein. C) Mean values [arbitrary units (AU)] ± SEM of HSL protein 
with obesity (LN CON vs. OB CON, not significant) and RSG treatment (not 
significant [n.s.]). D) GPAT activity with obesity (LN CON vs. OB CON, n.s.) and 
RSG treatment (OB CON vs. OB RSG, n.s.; n=9/group). 
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  Diacylglycerol is known to translocate PKC from the cytosolic to the 
membrane fraction resulting in its activation, and PKC has been implicated in 
the insulin resistance of skeletal muscle (10,11). Accordingly, the cytosolic and 
membrane fraction protein content of several diacylglycerol-sensitive PKC 
isoforms were measured.  There was no change in either total PKC-θ, -α/β, or -
δ protein, or in the membrane fractions of these PKC isoforms with obesity, or 
Rosiglitazone treatment (Figure 3.4, Table 3.2). 
 
Table 3. 2 Membrane/total protein ratio of diacylglycerol-sensitive PKC 
isoforms from LN CON, OB CON, and OB RSG rats.   
 LN CON OB CON OB RSG 
PKC α/β 0.31 ± 0.05 0.35 ± 0.04 0.38 ± 0.04 
PKC θ 0.90 ± 0.01 0.95 ± 0.02 0.93 ± 0.02 
PKC δ 0.76 ± 0.02 0.80 ± 0.01 0.82 ± 0.03 
 
 
Figure 3. 4 Protein kinase C (PKC) distribution.   
Representative immunoblots of PKC-θ,-δ, and -α/β.  Soleus muscles were 
homogenized, and the cytosolic and membrane fractions were separated using 
subcellular fractionation (see section 3.2). Proteins were quantified by Western 
blot analysis and densitometry.  There were no significant differences between 
groups (n=9/group). 
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 Increased skeletal muscle lipid content with obesity and Rosiglitazone 
were associated with changes in FA composition (Figure 3.5).  The proportion 
of monounsaturated fatty acids (MUFA) was elevated in obese (38.0 ± 0.8 %) 
compared with lean rats (29.1 ± 0.8 %, P<0.0001), and was further elevated by 
Rosiglitazone (43.7 ± 2.5 %, P=0.05).  The elevation in % MUFA observed in  
obese rats was due to specific increases in palmitoleate [16:1(n-7), P<0.0001] 
and oleate [18:1(n-9)] (P<0.0001) fatty acids, in conjunction with decreases in 
the proportions of stearate (18:0, P<0.0001) and linoleate [18:2 (n-6), 
P<0.0001].  The additional increase in % MUFA observed following 
Rosiglitazone treatment was solely due to an increase in 16:1 (n-7) (Figure 3.5, 
P=0.02). 
 
 
Figure 3. 5 Fatty acid (FA) composition of muscle triacylglycerol.  
A) Molar percentage of total FA for specific fatty acyl species (palmitate 16:0, 
palmitoleate 16:1, stearate 18:0, oleate 18:1, linoleate 18:2). B) Proportion of 
polyunsaturated species (PUFA), monounsaturated species (MUFA), and 
saturates within the muscle lipid pool. *, P < 0.05, LN CON vs. OB CON; #, P < 
0.05, OB CON vs. OB RSG (n=9/group). 
 65
 3.4 Discussion and Conclusions 
 The novel finding of the current study was that despite a normalisation of 
glucose tolerance, six weeks of Rosiglitazone treatment increased IMTG (1.3-
fold), diacylglycerol (1.7-fold) and ceramide (2-fold) in the skeletal muscle of 
obese, insulin resistant rats.  These results suggest, therefore, that the 
improvements in glucose tolerance seen with Rosiglitazone treatment are not 
mediated by reductions in the total content of these muscle lipids.  Furthermore, 
increased diacylglycerol was not associated with increased membrane-
associated PKC-θ, -α/β, or -δ content (Fig. 3.4, Table 3.2).  Since diacylglycerol-
induced insulin resistance in skeletal muscle is thought to be mediated by PKC 
translocation to the sarcolemma (Schmitz-Peiffer et al. 1997; Qu et al. 1999; 
Montell et al. 2001), this provides further evidence that the insulin-sensitising 
effects of Rosiglitazone in skeletal muscle are not lipid-mediated.  It is important 
to note that the improved glucose tolerance with Rosiglitazone observed in the 
current study was not necessarily due to increased skeletal muscle glucose 
uptake, and may involve increased hepatic or adipose glucose uptake, 
decreased gluconeogenesis and/or increased insulin secretion during the 
glucose challenge.  However, direct measurement of insulin-stimulated glucose 
uptake following chronic Rosiglitazone treatment has previously shown an 
increase in skeletal muscle glucose transport despite increased IMTG content 
(Muurling et al. 2003). 
 The effect of Rosiglitazone treatment on skeletal muscle lipid storage is 
unclear, as previous investigations have reported a decrease (Hockings et al. 
2003; Jucker et al. 2003; Kim et al. 2003a; Koh et al. 2003; Kuhlmann et al. 
2003), an increase (Muurling et al. 2003), or no effect (Mayerson et al. 2002; 
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Kuhlmann et al. 2003) on IMTG content.  Most studies demonstrating 
decreased IMTG content with Rosiglitazone have analysed muscle with a large 
proportion of type II fibres (Hockings et al. 2003; Jucker et al. 2003; Kim et al. 
2003a).  In contrast, in the present study muscle with predominantly (>90%) 
type I composition was analysed because type I muscle fibres contain more 
ectopic lipids (He et al. 2001), have a greater role in lipid utilisation (Dyck et al. 
1997) and are more insulin sensitive than type II fibres (Henriksen et al. 1990).  
The conflicting reports among laboratories analysing different muscle groups 
present the possibility that Rosiglitazone action may be fibre-type dependent.  
In order to test this, the IMTG content of a more highly glycolytic muscle (EDL; 
>50% type IIB fibers) was also analysed, and no increase in IMTG with 
Rosiglitazone treatment was found.  This suggests that oxidative fibres may be 
more responsive to Rosiglitazone treatment than glycolytic fibers. This also 
raises the possibility of contamination by extramyocellular adipocytes when 
using chemical extraction to measure IMTG, as a previous study using 1H-
nuclear magnetic resonance spectroscopy demonstrated increased 
extramyocellular lipid content in human skeletal muscle following RSG 
treatment (Mayerson et al. 2002).  However, contamination of a muscle sample 
by extramyocellular adipocytes can be avoided if a thorough removal of adipose 
tissue under magnification is performed (Guo 2001). It is believed that our 
samples were not contaminated with extramyocellular adipocytes since 
thorough microsdissection was performed.  Furthermore, HSL activity, which 
was measured using the same aliquot of freeze-dried tissue as IMTG, was 
decreased in obese Rosiglitazone treated rats.  If there was significant 
adipocyte contamination, one would expect HSL activity to be elevated because 
of its high expression in adipocytes compared with myocytes. Similarly, GPAT is 
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also highly expressed in adipose tissue and was not different between 
treatment groups. 
 The decrease in HSL activity (Fig. 3.3) is a potential mechanism for 
increased IMTG and diacylglycerol following RSG treatment. HSL is a 
regulatory enzyme for skeletal muscle IMTG degradation (Holm et al. 2000) and 
Rosiglitazone treatment caused a significant decrease in HSL activity that was 
not associated with changes in total protein content.  GPAT activity was also 
examined because it is the first committed step in glycerolipid synthesis and 
was found to be similar in all groups and was unaffected by Rosiglitazone. 
Taken together, these data are consistent with the increased IMTG observed 
after Rosiglitazone treatment.  HSL is also an important diacylglycerol lipase as 
demonstrated by diacylglycerol accumulation in HSL -/- mice (Haemmerle et al. 
2002).  The downregulation of HSL in the present study is also likely to be 
responsible for diacylglycerol accretion following Rosiglitazone treatment.   
 The consistent observation of increased lipid levels with Rosiglitazone 
may also be due to altered fatty acid (FA) transport and oxidation.  
Rosiglitazone increases sarcolemmal FA transport in primary skeletal muscle 
cell culture, which is associated with increased fatty acid translocase expression 
(Wilmsen et al. 2003).   Such increases in sarcolemmal FA transport, if present 
during chronic Rosiglitazone treatment, would likely result in skeletal muscle 
lipid deposition if they were not matched by similar increases in FA oxidation.  
Rosiglitazone does not appear to alter whole-body FA oxidation (Mayerson et 
al. 2002); however, other PPAR-γ agonists (eg: Troglitazone) have been 
reported to increase (Ide et al. 2000; Cha et al. 2001), or cause no change 
(Sreenan et al. 1999) in skeletal muscle FA oxidation in isolated preparations.  
The effect of Rosiglitazone on skeletal muscle FA oxidation has yet to be 
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examined, and may provide further insight into the observed changes in lipid 
levels following Rosiglitazone treatment. 
 Elevated intramyocellular lipid levels, in conjunction with increased 
insulin sensitivity appears counterintuitive given the abundance of evidence 
linking lipid accumulation and insulin resistance.  However, the composition of 
intramuscular lipid stores may provide a protective effect against insulin 
resistance in the face of increased lipid levels.  Since skeletal muscle insulin 
resistance has been directly correlated with the proportion of saturated fatty 
acids present in the triacylglycerol pool (Manco et al. 2000), the present study 
also investigated whether changes in specific fatty acid species occur in the 
muscle lipid pool with Rosiglitazone treatment.  Although there was no decrease 
in total saturated species with RSG, a shift towards a higher proportion of 
MUFA was observed, which was specifically due to an increase in palmitoleate 
[16:1 (n-7)].  Incubation of C2C12 myocytes with 16:1(n-7) had no deleterious 
effect on insulin-stimulated Akt phosphorylation (Chavez et al. 2003), however, 
incubation with the saturated species palmitate (16:0) and oleate (18:0) resulted 
in the incorporation of these fatty acids into ceramide (Chavez et al. 2003) and 
diacylglycerol (Montell et al. 2001; Chavez et al. 2003), and a decrease in 
insulin sensitivity.  Therefore, a shift towards the storage of monounsaturated 
species may provide protection from ceramide- and diacylglycerol- induced 
insulin resistance.  Further investigation of the effect of Rosiglitazone treatment 
on the incorporation of fatty acids into specific diacylglycerol and ceramide 
molecular species are warranted. 
 In summary, improved glucose tolerance after six weeks of Rosiglitazone 
treatment was associated with increased skeletal muscle IMTG, diacylglycerol 
and ceramide content.  Rosiglitazone-induced increases in lipid levels were 
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associated with decreased HSL activity and changes in the fatty acid 
composition of muscle lipids.  These results suggest that reducing intramuscular 
lipid accumulation is not the mechanism by which Rosiglitazone improves 
insulin-sensitivity.   
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CHAPTER FOUR: Chronic Rosiglitazone Treatment 
Restores AMPKα2 Activity in Insulin Resistant Skeletal 
Muscle 
 
 
 
 
Adapted from: Lessard SJ, Chen ZP, Watt MJ, Hashem M, Reid JJ, Febbraio 
MA, Kemp BE, Hawley JA. (2006) Am J Physiol Endocrinol Metab 290:251-257. 
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4.1 Introduction 
 Skeletal muscle insulin resistance is a common state associated with 
inactivity, ageing, genetic predisposition and environmental factors and is a 
hallmark feature of a variety of disease states including obesity, hyperlipidemia, 
hypertension and type 2 diabetes (Saltiel 2000). Rosiglitazone is a member of 
the Thiazolidinedione (TZD) class of oral antidiabetic agents that improves 
insulin sensitivity in a range of insulin-resistant states (Inzucchi et al. 1998; 
Hallsten et al. 2002). TZDs are peroxisome proliferator-activated receptor-γ 
(PPARγ) agonists that, upon activation by fatty acids (FA) or FA-derived 
compounds, bind to responsive elements located in the promoter regions of 
many genes and modulate their transcriptive activities (Saltiel and Olefsky 
1996; Auwerx 1999). Although PPAR-γ plays a role in the TZD-induced insulin 
sensitization, metabolic responses to TZDs can be dissociated from PPARγ-
induced gene transcription (Fujiwara et al. 1988; Ranganathan and Kern 1998; 
Brunmair et al. 2001).  Furthermore, the study described in chapter three 
reported that Rosiglitazone improves glucose tolerance by mechanisms other 
than a reduction of fatty acid accumulation within skeletal muscle. Hence, it is 
likely that there exist PPARγ independent mechanisms by which TZDs improve 
insulin sensitivity.   
 The AMPK-activated protein kinase (AMPK) is a cellular energy sensor 
that regulates glucose and lipid metabolism by phosphorylating key regulatory 
enzymes (Winder and Hardie 1999; Kemp et al. 2003). AMPK activation causes 
many metabolic changes that would be beneficial to individuals with type 2 
diabetes and the metabolic syndrome including increased glucose uptake and 
metabolism by muscle, decreased glucose production by the liver, and 
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decreased synthesis and increased oxidation of fatty acids (Winder and Hardie 
1999; Hardie 2003).  As TZDs increase insulin-stimulated glucose uptake and 
utilization, and decrease circulating levels of free fatty acids and triglycerides 
[for reviews see (Saltiel and Olefsky 1996; Olefsky 2000)], it is reasonable that 
a component of the insulin sensitizing effect of these drugs could be mediated 
through the action of the AMPK pathway.  In this regard, Fryer et al. (2002) 
reported that acute incubation of H-2Kb muscle cells with Rosiglitazone 
increased the AMP/ATP ratio and activated both α1- and α2- containing AMPK 
isoforms, which lead to a marked increase in the phosphorylation of acetyl-CoA 
carboxylase (ACC).  Furthermore, AMPK has been reported to phosphorylate 
IRS1 at Ser789 and enhance p85 docking, consistent with improving insulin 
signalling  (Jakobsen et al. 2001).  
  In the present study, the effects of acute Rosiglitazone administration in 
L6 muscle cells was compared with chronic Rosiglitazone treatment in skeletal 
muscle from obese, glucose intolerant Zucker rats on AMPK regulation and its 
downstream phosphorylation target, ACC. It was found that Rosiglitazone 
treatment normalises AMPKα2 activity in the skeletal muscle of obese Zucker 
rats to a level comparable to their lean litter-mates.  
 
4.2 Materials and Methods 
Animals 
 Female obese Zucker (fa/fa) and age-matched lean (fa/?) rats were 
obtained from Monash Animal Services (Victoria, Australia) at 19 wk of age.  
Rats were housed under controlled light (12:12 light:dark) at an ambient 
temperature of 21oC. Animals had free access to standard rat chow and water 
except when overnight fasting was required for blood measurements.  All 
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procedures were approved by the RMIT University Animal Ethics Committee. 
Obese rats were randomly divided into two experimental groups: control (OB 
CON, n=9) and Rosiglitazone (OB RSG, n=9).  The lean rats were treated with 
vehicle (LN CON, n=9) and acted as a control group for OB CON. Rats were 
dosed daily, for 6 wk, by oral gavage with either vehicle, which consisted of 
0.5% carboxymethylcellulose (CMC) (100 µL/100 g body mass; Sigma-Aldrich 
Inc, MO, USA), or 3 mg/kg Rosiglitazone (GlaxoSmith Kline, Stevenage, UK) 
suspended in an equal volume of CMC.  Following the 6 wk experimental 
period, rats were overnight fasted and euthanized by CO2 asphyxia, followed by 
exsanguination.  The time interval between CO2 administration and muscle 
harvesting was ~1-2 min, and the interval between the last Rosiglitazone 
treatment and tissue collection was ~24 h. The red gastrocnemius muscles 
were rapidly dissected from the rat hindlimbs, snap- frozen in liquid nitrogen and 
stored at –80°C for later analysis. 
Muscle metabolite and adenine nucleotide contents  
 Red gastrocnemius muscle was freeze-dried, powdered, and cleaned of 
all visible connective tissue and blood under magnification.  A ~2 mg aliquot 
was then taken and extracted in 0.5 M HClO4 (1 mM EDTA; Sigma-Aldrich Inc., 
MO, USA) and neutralised with 2.2 M KHCO3 (Merck Pty Ltd., VIC, Australia). 
Muscle ATP, PCr, creatine and lactate were measured, and muscle ADP and 
AMP calculated as described for cells. Muscle for glycogen analysis was 
extracted in 2M HCl (Merck Pty Ltd., VIC, Australia) and neutralised with 0.67 M 
NaOH (Sigma-Aldrich Inc., MO, USA) and glycogen content was determined by 
fluorometric techniques (Passonneau and Lauderdale 1974). 
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AMPK activity and AMPK subunit protein expression  
 Approximately 80 mg of wet muscle was homogenized in buffer A (50 
mM Tris HCl, pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothretiol, 50 mM 
NaF, 5mM Na pyrophosphate, 10% glycerol, 1% Triton X-100, 10mg/mL trypsin 
inhibitor, 2 mg/mL aprotinin, 1 mM benzamidine, 1 mM phenylmethylsulfonyl 
fluoride) [all from Sigma-Aldrich Inc., MO, USA].  The muscle homogenate was 
then centrifuged at 20,000 x g for 25 min, and the supernatant was collected.  
The supernatant was aliquoted for determination of i) protein concentration 
(Pierce, Rockford, IL, USA), ii) immunoprecipitation (AMPK α1, α2), iii) ACC 
affinity purification, and iv) protein expression by Western blotting (UCP3).  
Aliquots were stored at –80°C until use, and immunoprecipitates were used to 
determine protein content and enzyme activity (AMPK -α1, -α2) [described 
below]. 
Immunoprecipitation 
 Approximately 5 mg of protein from the supernatants was incubated with 
AMPK-α1 or AMPK-α2 antibody-bound protein A sepharose beads (6MB, 
Amersham Biosciences, Uppsala, Sweden) for 2 h at 4°C. The polyclonal 
antipeptide antibodies to AMPK α1 and α2 were raised to non-conserved 
regions of the AMPK isoforms -α1 (rat 231-251) and -α2 (rat 351-366).  
Immunocomplexes were washed with PBS and suspended in 50 mM Tris (pH 
7.5) buffer for the AMPK activity assay (Christopher et al. 2003). The AMPK 
activities in the immune complexes were measured in the in the presence of 
200 mM AMP (Sigma-Aldrich Inc., MO, USA). Activities were calculated as 
picomoles of phosphate incorporated into the SAMS peptide per min, per 
milligram of protein subjected to immunoprecipitation (pmol/min/mg).  Acetyl 
CoA carboxylase (ACC) was affinity purified by incubating the post-AMPK 
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immunoprecipitation supernatants in Streptavidin Sepharose High Performance 
beads (Amersham Biosciences, Uppsala, Sweden) for 1 h at 4°C. 
Western Blotting 
 The affinity-purified ACC fraction was electrophoresed on 7.5% SDS-
PAGE and detected by immunoblotting with anti-phospho-Ser218-ACC 
polyclonal antibody (Chen et al. 2000).  The blots were then stripped (Restore 
Western Blot Stripping Buffer, Pierce Biotechnology, Inc.) at 37oC for 20 min, 
blocked, and incubated with horseradish peroxidase conjugated Streptavidin 
(Amersham Pharmacia Biotech UK, Little Chalfont, UK) to determine total ACC.  
Aliquots of immunoprecipitated AMPK -α1, and -α2 proteins were 
electrophoresed on 10% SDS-PAGE and detected by immunoblotting with anti-
phospho-Thr172 antibody, raised against AMPK alpha peptide 
(KDGEFLRpTSCGSPNY) as described previously (Clark et al. 2004).  The 
membranes were then stripped (see above), washed in PBS, blocked for 60 min 
in 5% skim milk powder/PBS, and reprobed with antibodies specific for the 
AMPK α-1, and α-2 isoforms.  Aliquots containing 80 µg total protein were 
electrophoresed on 15 % SDS-PAGE and detected by immunoblotting with anti-
UCP3 antibody (Alpha Diagnostic Intl. Inc., San Antonio, TX). 
Cell Culture 
 L6 myoblasts were maintained at 37°C (95% O2 / 5% CO2) on 60 mm 
collagen-coated plastic dishes in α-modified Eagle’s medium (α-MEM; SAFC 
Biosciences, VIC, Australia) containing 10% fetal bovine serum (FBS; SAFC 
Biosciences, VIC, Australia) culture media and 1% penicillin/streptomycin 
(Invitrogen Australia Pty Ltd., VIC, Australia), and 5mM glucose (Sigma-Aldrich 
Inc., MO, USA). Differentiation was induced by switching to medium containing 
2% horse serum (Invitrogen Australia Pty Ltd., VIC, Australia) when the 
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myoblasts were ~90% confluent. Experimental treatments were started after 4 
days, by which time nearly all of the myoblasts had fused to form myotubes.  
Experimental Protocol 
 To determine the effect of Rosiglitazone treatment on AMPK activity, 
AMPK Thr172 phosphorylation and ACC Ser218 phophorylation, L6 myotubes 
were incubated with 0 (DMSO; Sigma-Aldrich Inc., MO, USA), 5, 50, or 200 µM 
Rosiglitazone for 30 min at 37°C.  Following incubation, cells were rinsed 3× 
with PBS and lysed with 200 µL of buffer A.  Lysates were immediately frozen in 
liquid N2 and kept at –80°C until further analysis.  AMPKα1 and α2 subunits, 
and ACCβ protein were isolated by immunoprecipitation and affinity 
chromatography, respectively, as described above.  AMPK activity was 
determined using the SAMS peptide assay, and protein expression and 
phosphorylation were determined (described above). 
Palmitate oxidation 
 To examine the effects of Rosiglitazone on fat oxidation, cells were 
grown in 60 mm plates and were incubated for 1 h in the absence (DMSO, n=6) 
or presence of 5 (n=6), or 200 (n=6) µM Rosiglitazone in 3 mL of media 
consisting of α-MEM, 2% BSA and 0.5 mM 14C-palmitate (Amersham 
Biosciences, Castle Hill, NSW, Australia).  Following the incubation period the 
reaction was stopped, and 2 mL of media was added to an equal volume of 1 M 
acetic acid and the released 14CO2 was collected in benzothonium hydroxide 
(Sigma-Aldrich Inc., MO, USA).  The cells were rinsed twice with PBS, methanol 
was added to the plate, and cells were scraped for subsequent analysis of the 
acid soluble metabolite (ASM) fraction.  The 14C content of both fractions were 
determined using scinitillation counting and the oxidation rates (CO2 + ASM) 
were calculated. 
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Metabolite Analysis 
 L6 myotubes were incubated with DMSO (Vehicle), 200 µM 
Rosiglitazone, 500 µM DNP, or 200 µM AICAR for 30 min.  The medium was 
removed and the cells were rinsed 3× with PBS, lysed with 100 µl 0.5 M HClO4 
(in 1 mM EDTA; Sigma-Aldrich, Inc., MO, USA), and neutralized with 2.2 M 
KHCO3 (Sigma-Aldrich, Inc., MO, USA). This extract was used for the 
determination of adenosine triphosphate (ATP), phosphocreatine (PCr), 
creatine and lactate by enzymatic fluorometric assays (Bergmeyer 1974). Free 
ADP and AMP concentrations were calculated with the assumption of 
equilibrium of the adenylate kinase and creatine kinase reactions (Dudley et al. 
1987). Free ADP was calculated using the measured ATP, creatine and PCr 
values, an estimated H+ concentration (Sahlin et al. 1976) and the creatine 
kinase equilibrium constant of 1.66 x 109. Free AMP concentration was 
calculated from the estimated free ADP and measured ATP with the adenylate 
kinase constant of 1.05. 
4.2.1 Statistical Analysis 
 Results are presented as means ± SE.  Statistical analysis of skeletal 
muscle measures was performed using an unpaired Student’s t-test.  Analysis 
of cell culture experiments was undertaken using one-way ANOVA.  A P value 
of <0.05 was considered significant.  Where ANOVA revealed significant 
differences, Neuman Keuls post-hoc test was used to locate such differences.  
4.3 Results 
Effects of acute incubation of muscle cells with Rosiglitazone 
 Table 4.1 displays the AMP:ATP ratio of L6 myotubes following 
incubation with DMSO (control), 200 µM Rosiglitazone, 500 µM DNP, or 200 µM 
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AICAR for 30 min.  Incubation with DNP caused a 2.4-fold increase in AMP: 
ATP (P=0.02 vs. control).  No change in AMP: ATP was observed following 
Rosiglitazone or AICAR treatment.  
 
Table 4. 1 AMP (free)/ATP ratios from L6 myotubes treated with 
Rosiglitazone, AICAR, or DNP 
Treatment  AMP(free) : ATP ratio (× 1000) 
Control (DMSO, n=6) 0.010 ± 0.003 
200 µM Rosiglitazone (n=6) 0.007 ± 0.001 
500 µM DNP (n=4) 0.024 ± 0.006* 
200 µM AICAR (n=4) 0.011 ± 0.001 
Values are means ± SEM.  *P<0.05 vs. Control. 
 
Figure 4.1 shows the effect of varying concentrations of Rosiglitazone on 
the activity of   AMPKα1 isoform (4.1A) and Thr172 phosphorylation of AMPK 
α1 (4.1B), while Figure 4.2 displays the ACC Ser218 phosphorylation [Figure 
4.2A] and palmitate oxidation (Figure 4.2B) in L6 myotubes following acute 
incubation. The dose-response trend of increasing AMPKα1 activity was 
significant at a dose of 200 µM Rosiglitazone (P<0.05), and corresponded with 
similar increases in Thr172 phosphorylation of the AMPKα1 isoform (Figure 
4.1B).  Increased AMPKα1 activity in L6 myotubes at the highest dose of 
Rosiglitazone was also associated with a 3-fold increase in the ACC Ser218 
phosphorylation compared to control (0 vs. 200 µM Rosiglitazone; P<0.05; 
Figure 4.2A) and a significant increase in palmitate oxidation (0 vs. 200 µM 
RSG; 391 ± 20 vs 455 ± 19 pmol/h, respectively; Figure 4.2B). AMPKα2 activity 
in L6 myotubes was undetectable. 
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Figure 4. 1 Activation of AMP-activated protein kinase (AMPK) by 
phosporylation in Rosiglitazone-treated L6 myotubes.  
(A) AMPK activity measured using the SAMS peptide assay of AMPKα1 protein 
isolated by immunoprecipitation from L6 myotubes incubated with 0 (DMSO), 5, 
50, or 200 µM RSG for 30 min (B) ratio of AMPKα1 protein phosphorylated at 
Thr172 (pT172) to total levels of AMPKα1 protein, as determined by Western 
blotting (representative blots shown) in L6 myotubes incubated with increasing 
concentrations of RSG. *P < 0.05 vs. 0 µM RSG (n=6/group). 
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Figure 4. 2 Increased acetyl-CoA carboxylase (ACC) phosphorylation 
and palmitate oxidation in Rosiglitazone-treated L6 myotubes.  
(A) ratio of ACC protein phosphorylated at Ser218 to total ACC protein 
(pACC/total ACC) in L6 myotubes treated with 0 (DMSO), 5, 50, or 200 µM 
RSG for 30 min. (B) rate of [14C]-palmitate oxidation in L6 myotubes treated with 
0, 5, or 200 µM RSG for 1 h. *P < 0.05 vs. 0 µM RSG (n=6/group). 
 
 
Effects of chronic Rosiglitazone treatment in skeletal muscle 
 Table 4.2 displays the resting nucleotide and metabolite concentrations 
for the three groups under investigation. There were no differences in ATP, 
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AMP, or ADP concentrations between muscle from lean or obese control 
animals, or obese muscle treated with Rosiglitazone.  Consequently, there were 
no changes in the AMP/ATP ratio for any group (Table 4.2). Resting 
concentrations of phosphocreatine, creatine and lactate were also similar 
between groups. However, glycogen content was elevated in muscle from 
obese compared to lean animals (P<0.05), and this remained high in 
Rosiglitazone treated rats.   
 
Table 4. 2 Resting skeletal muscle nucleotide and metabolite 
concentrations from LN CON, OB CON, and OB RSG rats.  
 LN CON OB CON OB RSG 
Nucleotides  
ATP (mmol/kg dm) 19.3 ± 0.7 21.5 ± 1.2 18.2 ± 2.1 
Free AMP (µmol/kg dm) 0.42 ± 0.08 0.56 ± 0.16 0.49 ± 0.11 
Free ADP (µmol/kg dm) 80.7 ± 7.1 95.4 ± 18.2 90.1 ± 15.2 
AMP:ATP (× 1000) 0.022 ± 0.004 0.028 ± 0.008 0.027 ± 0.005 
Metabolites  
(mmol/kg dm) 
Phosphocreatine 67.1 ± 4.5 58.3 ± 5.1 60.5 ± 8.9 
Creatine  28.0 ± 2.0 23.2 ± 4.0 27.8 ± 2.0 
Lactate  35.9 ± 2.0 33.0 ± 2.7 39.6 ± 1.5 
Glycogen  43.2±3.6 87.9±7.8* 91.4±7.2 
Values are means ± SEM, n = 5-7.   * P<0.05, vs. LN CON (n=9/group). 
 
 The activities of the AMPK-α1 and -α2 isoforms along with the ACC 
Ser218 phosphorylation from skeletal muscle of animals treated for 6 wk with 
Rosiglitazone are shown in Figure 4.3. The activity of AMPKα1 was similar in 
lean and obese animals and was unaffected by 6 wk Rosiglitazone treatment 
(Figure 4.3A).  In contrast, the activity of the AMPKα2 isoform was two-fold 
lower in obese versus lean animals (7.45 ± 1.0 vs. 15.7 ±2.2 pmol/mg/min; 
P<0.05), but was restored to lean control values following Rosiglitazone 
treatment (OB RSG: 14.2 ± 1.5 pmol/mg/min ; Figure 4.3B).  The observed 
changes in AMPKα2 activity were most likely due to corresponding changes in 
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protein expression, rather than changes in phosphorylation of the protein at the 
T172 residue, which was similar in all groups (data not shown).  Altered 
AMPKα2 activity with obesity and after Rosiglitazone treatment paralleled 
changes in the phosphorylation state of its target protein, ACC.  The ratio of 
phosphorylated ACC to total ACC protein (pACC/Total ACC) was significantly 
decreased in muscle from obese animals (P<0.05), but was restored to lean 
control levels following Rosiglitazone treatment (Figure 4.3C).  AMPKα1 protein 
expression tended to be higher (p=0.06) in muscle from obese than lean control 
animals, but was significantly decreased after Rosiglitazone treatment (P<0.05; 
OB CON vs OB RSG; Figure 4.4A).  There were reciprocal changes in the 
protein expression of the AMPKα2 isoform, which was lower in muscle from 
obese animals, but restored to lean control values after chronic Rosiglitazone 
treatment (Figure 4.4B).  
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Figure 4. 3 Increased skeletal muscle AMP-activated protein kinase 
(AMPK)-α2 activity in obese rats after chronic Rosiglitazone (RSG) 
treatment.  
Activity of AMPKα1 (A) and AMPKα2 (B) isoforms in muscle taken from lean 
(LN CON), obese (OB CON), and RSG-treated (OB RSG) rats. Activity was 
measured using the SAMS peptide assay in protein isolated by 
immunoprecipitation of muscle lysates. C: pACC/total ACC ratio from the 
skeletal muscle of LN CON, OB CON, and OB RSG rats. *P < 0.05 vs. LN CON; 
#P < 0.05 vs. OB CON (n=9/group). 
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Figure 4. 4 Isoform-specific changes in AMP-activated protein kinase 
(AMPK) protein with obesity and Rosiglitazone (RSG) treatment.  
  
Mean levels [arbitrary units (AU), n = 8] of AMPKα1 (A) and AMPKα2 (B) 
protein from LN CON, OB CON, and OB RSG rats. Proteins were isolated from 
skeletal muscle lysates by immunoprecipitation and quantified using Western 
blot analysis and densitometry. *P < 0.05 vs. LN CON; #P < 0.05 vs. OB CON 
(n=9/group). 
 
 
 Figure 4.5 displays the protein levels of UCP3 in skeletal muscle of lean 
and obese animals after Rosiglitazone treatment.  UCP3 protein abundance 
was not different between lean and obese animals.  However, Rosiglitazone 
treatment resulted in a significant increase in UCP3 protein levels (P<0.05).  
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Figure 4. 5 Uncoupling protein-3 (UCP3) protein expression with 
Rosiglitazone (RSG) treatment. 
Mean levels (AU, n = 8) of UCP3 protein from LN CON, OB CON, and OB RSG 
rats. Skeletal muscle protein was quantified using Western blot analysis and 
densitometry. #P < 0.05 vs. OB CON (n=9/group). 
 
4.4  Discussion 
 TZD’S are known to improve insulin sensitivity by activating PPAR-γ and 
inducing adipogenesis in adipose tissue (Day 1999) but also via PPAR-γ 
independent mechanisms.  In the present study, Rosiglitazone increased AMPK 
activity leading to phosphorylation of ACC in vitro and in vivo.   
 Maximal activation of AMPK was observed in L6 myotubes when treated 
with 200 µM Rosiglitazone, due to an increase in the activity of the AMPKα1 
isoform. Moreover, the increased AMPKα1 activity at the highest dose of 
Rosiglitazone was associated with a marked increase in the phosphorylation of 
ACC and a concomitant increase in palmitate oxidation. Recently, Cha et al. 
(Cha et al. 2005) reported cultured muscle cells from type 2 diabetic patients 
had lower rates of basal β-oxidation, but that this defect was normalized after 
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chronic (4 d) TZD treatment.  Accordingly, an AMPK-stimulated increase in lipid 
oxidation may be one mechanism by which Rosiglitazone exerts its insulin-
sensitising effect. 
 Only one previous study has examined the effect of Rosiglitazone on 
AMPK activity in skeletal muscle myotubes. Fryer et al. (2002) observed that 
treating muscle cells derived from heterozygous H-2Kb tsA58 transgenic mice 
with Rosiglitazone lead to increases in the AMP/ATP ratio and a concomitant 
increase in AMPK activity.  In the present study an increase in AMPK activity in 
Rosiglitazone treated cells was also observed. However, no difference in the 
energy charge (AMP/ATP) of the cell was detected, suggesting that 
Rosiglitazone’s action was exerting an energy charge independent effect on 
AMPK. The reasons for the differences in results between the present and 
previous study (Fryer et al. 2002) in terms of AMP: ATP ratio, are not readily 
apparent.  The H-2Kb cell line contains both AMPK -α1 and -α2 isoforms (Fryer 
et al. 2002) and we cannot rule out the possibility that this is a more sensitive 
cell line to treatments that affect energy charge.  However, it should be noted 
that the H-2Kb line are immortalized cells derived from the simian virus 40 
(SV40) large tumor (T) antigen (TAg) transgenic mouse (Jat et al. 1991) and 
may have some limitations with respect to their physiological significance. In 
order to be consistent in the present investigation, L6 myotubes derived from rat 
skeletal muscle were used so that the acute effects of Rosiglitazone might be 
compared with the chronic effects of this treatment regimen in obese Zucker 
rats. 
 Previous studies have suggested that altered skeletal muscle AMPK 
activity may not play a role in obesity and diabetes (Musi et al. 2001; Hojlund et 
al. 2004; Steinberg et al. 2004; Wojtaszewski et al. 2005).  However, a recent 
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study (Chen et al. 2005) found that although basal AMPK activity was not 
altered, AMPK activation was impaired in cultured human skeletal muscle from 
obese type 2 diabetics.  There is also evidence that basal AMPK 
phosphorylation is reduced in the cardiac muscle of both Zucker diabetic fatty 
rats and ob/ob mice (Wang and Unger 2005), and that this defect is normalized 
by TZD treatment.  Further study is clearly needed in order to draw general 
conclusions on the role of skeletal muscle AMPK defects in obesity and 
diabetes.  
 To date, no studies have determined the effects of chronic Rosiglitazone 
treatment on the responses of AMPK in skeletal muscle or, more importantly, 
the effect of Rosiglitazone on skeletal muscle from insulin resistant animals. Our 
finding that chronic Rosiglitazone treatment increased both AMPKα2 and ACC 
phosphorylation in obese Zucker rats is of major clinical significance given the 
widespread use of TZDs as an anti-diabetic drug.  The altered AMPKα2 activity 
with obesity and Rosiglitazone treatment corresponded with changes in the 
phosphorylation state of its target protein, ACC, which was decreased with 
obesity, but was restored to the level of lean controls after Rosiglitazone 
administration. Of interest was the reciprocal response of the AMPK protein 
levels to the chronic Rosiglitazone administration: AMPKα2 protein was 
reduced in obesity but restored to lean control values after Rosiglitazone 
treatment, while AMPKα1 protein abundance was suppressed with treatment.  
Consistent with our in vitro cellular data, the muscle nucleotide concentrations 
were unaltered by chronic Rosiglitazone treatment in vivo (Table 4.2).   
 Since hypoxia stimulates AMPK activity and a catecholamine response 
(Borovsky et al. 1998; Hallsten et al. 2002), the combination of euthanasia by 
CO2 asphyxiation and the elapsed time between tissue collection and freezing 
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may have resulted in an altered intracellular environment that could contribute 
to changes in AMPK activity.   These factors are potential limitations of the 
current study. However, we are confident that the observed AMPK activation in 
the present study was not due to hypoxia for the following reasons.  First, 
muscle metabolites were within the expected ranges for all treatment groups 
and were similar to those obtained by other groups studying Obese Zucker rats 
(Klein et al. 1994; Ranganathan and Kern 1998).   Second, the observed 
changes in AMPK activation were paralleled by changes in AMPK protein levels 
(Figure 4.4) and were not associated with changes in the T172 phosphorylation 
of AMPK.  This suggests that the increase in activity was due to chronically 
altered protein levels, rather than acute changes in cellular energy status.  
Finally, the time taken to extract muscle was not different between groups and 
therefore, any differences in AMPK activity are indicative of the treatment. 
 The improved metabolic action as a consequence of up-regulating 
AMPKα2 by Rosiglitazone may be due to an increase in fat oxidation, since 
increased β-oxidation in muscle cells has been shown to enhance insulin-
stimulated glucose metabolism and protect against insulin resistance in the face 
of elevated intramyocellular lipid content (Perdomo et al. 2004).  Future studies 
should determine whether the observed increase in skeletal muscle AMPK 
activity with chronic Rosiglitazone treatment is associated with a concomitant 
increase in fat oxidation in vivo. However, it is also possible that Rosiglitazone-
mediated up-regulation of AMPKα2 may improve metabolic action via 
alternative mechanisms. Treatment with either Rosiglitazone (Brunmair et al. 
2004) or AICAR (5-aminoimidazole-4-carboxamide-1-beta-d-ribonucleoside) 
(Stoppani et al. 2002; Suwa et al. 2003) increases uncoupling protein 
expression in skeletal muscle. In addition, UCP3 over-expressing transgenic 
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mice display enhanced glucose tolerance and palmitate oxidation (Wang et al. 
2003), a phenotype compatible with chronic TZD treatment. In the present 
investigation we found that UCP3 protein expression was up-regulated by 
chronic Rosiglitazone treatment, suggesting that this protein may account for 
part of its metabolic action in skeletal muscle.  
 Previously Musi et al. (2002) reported that the antidiabetic drug 
metformin (biguanide) increased AMPKα2 activity in type 2 diabetic patients 
following a 10 wk treatment regime.   A significant increase in Thr172 
phosphorylation was observed but not a significant increase in AMPKα2 levels 
in the biopsy samples.  The increase in AMPKα2 activity seen in their study was 
paralleled by decreases in ACC activity consistent with AMPK mediated 
phosphorylation.   Previously, it has been suggested that metformin and 
Rosiglitazone activate AMPK by different pathways (Fryer et al. 2002), with 
Rosiglitazone causing an increase in AMP levels.  Irrespective of the 
mechanism of activation, both drugs (metformin, human type 2 diabetics; 
Rosiglitazone, obese Zucker rats) enhance AMPK signalling via the α2 isoform 
and inactivate ACC. 
 In conclusion, the results from the present study demonstrate that 
chronic Rosiglitazone administration stimulated isoform-specific regulation of 
the AMPK signalling cascade in skeletal muscle from obese Zucker rats and in 
myotubes in vitro. The increased basal activity of AMPKα2 paralleled changes 
in the phosphorylation state of its target protein, ACCβ, and occurred without 
detectable changes in cellular energy charge. These changes in AMPKα2 seem 
likely to be an important component of the insulin sensitizing effect of 
Rosiglitazone that contribute to the improved metabolic action associated with 
chronic TZD drug administration. Future studies should determine the 
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mechanisms underlying altered transcriptional regulation and/or turnover of 
AMPKα2 protein in skeletal muscle from obese Zucker rats, and how this is 
reversed by TZD treatment. 
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CHAPTER FIVE: Exercise, but not Rosiglitazone 
reverses lipid-induced impairments in muscle glucose 
and lipid metabolism:  Roles for AMPK and Akt/AS160 
 
 
Lessard SJ, Rivas DA, Chen ZP, Bonen A, Febbraio MA, Reeder DW, Kemp 
BE, Yaspelkis BB III, Hawley JA.  (2006)  In Review. 
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5.1 Introduction 
 
The clinical onset of insulin resistance typically involves a combination of 
aberrant glucose and lipid metabolism.  In skeletal muscle, an impaired ability to 
oxidise fatty acids (FA) and the accumulation of lipid species such as ceramide 
and diacylglycerol is associated with impaired insulin-stimulated glucose 
uptake, and whole-body insulin resistance (Bruce and Hawley 2004).  Acute 
increases in lipid availability result in reduced muscle glucose uptake, oxidation 
and glycogen synthesis (Randle 1998).  While these impairments to glucose 
metabolism following acute FA exposure have been largely attributed to 
impaired insulin signalling (Schmitz-Peiffer 2000), the effects of persistently 
elevated FA availability (i.e. obesity or high-fat feeding) in skeletal muscle are 
not known.  Due to the progressive nature of insulin resistance, it is likely that its 
clinical onset involves co-ordinated changes in gene transcription and protein 
expression, in addition to acute signalling events.  Furthermore, given the direct 
functional link between lipid and glucose homeostasis, it is plausible that 
chronic adaptations induced by increased FA supply involve pathways that are 
involved in the regulation of both lipid and glucose metabolism.   
Akt has recently been identified as a regulator of skeletal muscle lipid 
metabolism in addition to its well-established role in the insulin-signalling 
pathway (Bouzakri et al. 2006).  AMP-activated protein kinase (AMPK) also 
plays a dual role in the regulation of glucose uptake and storage, as well as FA 
turnover and utilization in skeletal muscle (Musi and Goodyear 2002) and may 
be involved in the etiology (Winder and Hardie 1999) and treatment (Musi and 
Goodyear 2002) of type 2 diabetes.  Thus, determining the effects of chronically 
elevated lipid availability on the Akt and AMPK signalling pathways may provide 
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insight into the impairments in glucose and lipid metabolism that underpin the 
insulin resistant state.  Furthermore, examining the biochemical and cellular 
mechanisms by which common treatments for insulin-resistance reverse 
impairments in both glucose and lipid metabolism may elucidate their specific 
modes of action. 
Both pharmacological intervention (i.e. thiazolidinediones [TZD]), and 
lifestyle modification (i.e. exercise training) are clinically effective treatments for 
improving whole-body insulin sensitivity (Inzucchi 2002; Hawley 2004; Pedersen 
and Saltin 2006).  However the mechanism(s) by which these therapies reverse 
lipid-induced insulin resistance in skeletal muscle is unclear.  It has been 
suggested that peroxisome proliferator-activated receptor agonists, such as 
Rosiglitazone, improve insulin sensitivity in skeletal muscle by preventing the 
toxic accumulation of lipids in this tissue (Hockings et al. 2003; Jucker et al. 
2003).  However, “lipid steal” directly from skeletal muscle following chronic 
Rosiglitazone treatment has not been consistently observed.  It has been 
suggested in chapter four and by Fryer et al. (2002) that Rosiglitazone activates 
AMPK in skeletal muscle, thereby enhancing glucose uptake and FA oxidation.  
Exercise training also has the ability to enhance AMPK signalling, glucose 
uptake and FA oxidation in muscle (Bruce and Hawley 2004), raising the 
possibility that combined treatment may produce additive effects in this tissue.  
Indeed, Hevener et al. (2000) demonstrated that the whole-body insulin-
sensitising effects of the PPARγ agonist, Troglitazone and exercise training 
were additive in obese Zucker rats (Hevener et al. 2000).  However, it is unclear 
whether these effects were attributable to improvements in skeletal muscle 
insulin sensitivity.  Furthermore, it is not known whether the combined insulin-
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sensitising effects of these treatments are associated with improvements in 
muscle lipid metabolism. 
Accordingly, we used a model of lipid-induced insulin resistance, the 
high-fat fed rat, to examine the independent and interactive effects of 
Rosiglitazone treatment and exercise training on insulin-stimulated glucose 
transport, FA oxidation and lipid accumulation in skeletal muscle.  In addition, 
the potential involvement of Akt and AMPK in these adaptations was examined 
because of their dual roles in lipid and glucose metabolism.  It was 
hypothesised that a combination of exercise training and Rosiglitazone 
treatment would result in additive improvements in skeletal muscle insulin 
sensitivity and lipid metabolism compared to either treatment alone. 
5.2 Materials and Methods 
 
Animals 
Male Sprague-Dawley rats (~4 wk of age) were given ad libitum access 
to a high-fat diet (HF; 58% kcal fat; Research Diets Inc., New Brunswick, NJ) 
and water for 4-wk to induce insulin-resistance.  During the subsequent 4-wk 
experimental period, rats continued to eat a high-fat diet and were randomly 
allocated to one of the following groups (n=16/group): control (HF CON), 
exercise training (HF EX), Rosiglitazone treatment (HF RSG), or a combination 
of both exercise training and Rosiglitazone treatment (HF EX RSG).  Exercise 
training consisted of treadmill running for 1 h/day, 5 day/wk on a 15% incline, at 
a speed that was gradually increased during the first week of training to 32 
m/min.  Rosiglitazone-treated rats received a diet containing 50 ppm 
Rosiglitazone (GlaxoSmith Kline, Stevenage, UK), which they consumed ad 
libitum at an average dose of 2.08 ± 0.06 mg/kg/day.   A fifth group of rats (CF 
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CON; n=16) was fed a normal chow diet (17% kcal fat; Research Diets Inc.) for 
the duration of the study (8 wk), and acted as a control for HF CON.  Following 
the experimental period, animals were fasted for 8-12 h prior to undergoing 
hindlimb perfusion for the measurement of insulin-stimulated 3-O-methylglucose 
transport (n=8/ treatment group), or 14C-palmitate uptake and oxidation 
(n=8/treatment group).   EX animals underwent their last training bout 36-48 h 
prior to hindlimb perfusion. 
Hind limb perfusions 
Rats were anaesthetized with an intraperitoneal injection of sodium 
pentobarbital (6.5 mg/100 g body mass) and surgically prepared for hind limb 
perfusion as previously described (Herr et al. 2005).  Briefly, cannulas were 
inserted into the abdominal aorta and vena cava, and the animals were killed 
via an intracardiac injection of pentobarbital as the hind limbs were washed out 
with 30 mL of Krebs-Henseleit buffer (KHB, pH 7.55; Sigma-Aldrich, Inc., MO, 
USA). The basic perfusate medium contained 30% washed time-expired human 
erythrocytes (Ogden Medical Center, Ogden, UT, USA) and was continuously 
gassed with a mixture of 95% O2- 5% CO2 and warmed to 37oC.  Perfusate flow 
rate was set at 7.5 mL/min during the stabilisation period and subsequent 
perfusion, during which rates of glucose transport or palmitate uptake were 
determined. 
Insulin-stimulated 3-O-methylglucose transport 
The cannulas were placed in line with a non-recirculating perfusion 
system and the hind limbs were allowed to stabilise during a 5 min washout 
period.  Perfusions were performed in the presence of 500 µU/mL insulin (Eli 
Lilly Pty Ltd, IN, USA). The hind limbs were washed out with perfusate 
containing 1 mM glucose (Sigma-Aldrich, Inc., MO, USA) for 5 min in 
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preparation for the measurement of glucose transport.  Glucose transport was 
measured over an 8 min period using a perfusate that  contained  8 mM of the 
non-metabolisable glucose analogue 3-O-methylglucose (3-MG; 32 µCi 3-
[3H0MG/mM, PerkinElmer Life Sciences, Boston, MA, USA) and 2 mM mannitol 
(60 µCi-[1-14C] mannitol/ mM, PerkinElmer Life Sciences) as an intracellular 
space marker.  Immediately following the transport period, portions of the red 
quadriceps (RQ) were excised from both hind limbs, blotted on gauze 
dampened with cold KHB, freeze clamped in liquid N2 and stored at -80oC for 
later analysis.  Rates of insulin stimulated skeletal muscle 3-MG transport were 
calculated as previously described (Yaspelkis et al. 2004). 
14C-Palmitate uptake and oxidation rates 
Rats were fasted for 8-12 h prior to being anaesthetized and having their 
right hind limb surgically prepared for perfusion.  Prior to cannulation, the left 
iliac vessels were tied off and portions of the red quadriceps muscle were 
immediately excised from the left hind limb, freeze clamped in liquid N2 and 
stored for later analysis.  This unperfused tissue was used for the analysis of 
AMP-activated protein kinase activity and phosphorylation.  Skeletal muscle FA 
metabolism was assessed as previously described (Todd et al. 2005) by 
perfusing hind limbs (7.5 mL/min) with a recirculated perfusate containing 4% 
FA-free bovine serum albumin (Sigma-Aldrich, Inc., MO, USA), 500 µM 
albumin-bound palmitate (Sigma-Aldrich, Inc., MO, USA), and 5 µCi of albumin-
bound [1-14C]palmitate (PerkinElmer) for 60 min (20 min equilibration period 
followed by a 40 min experimental period). Arterial and venous perfusate 
samples for the analysis of 14C palmitate were taken at 10, 20, 30 and 40 min of 
the experimental period.  Arterial and venous samples for the analysis of 14CO2 
were taken immediately following the equilibration period, and at 40 min.  
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Following the 40 min experimental perfusion period, muscle was excised and 
stored as described above.  To determine plasma palmitate radioactivity, 
duplicate 100 µL aliquots of the perfusate plasma were mixed with liquid 
scintillation fluid and counted in a liquid scintillation analyser.  The liberation and 
collection of 14CO2 from perfusate samples was performed by injecting 2 mL of 
anaerobically collected perfusate into a sealed, 10 mL flask containing an equal 
volume of 1 M acetic acid (Sigma-Aldrich, Inc., MO, USA).  The released 14CO2 
was trapped by an insert containing a strip of filter paper saturated with 500 µL 
of benzothonium hydroxide (Sigma-Aldrich, Inc., MO, USA).  The flask was kept 
sealed overnight to allow complete absorption of the released CO2 by 
benzothonium hydroxide, after which the insert was removed and placed into a 
scintillation vial where it was mixed with liquid scintillation fluid and counted in a 
liquid scintillation analyser. 
AMPK activity and AMPK subunit protein expression  
AMPK activity, pT172 phosphorylation and total protein content were 
analysed as previously described in chapter four.  Briefly, ~5 mg of protein from 
RQ muscle lysates were incubated with AMPKα1 or AMPKα2 antibody-bound 
protein A sepharose beads (6MB, Amersham Biosciences, Uppsala, Sweden) 
for 2 h at 4°C. The AMPK activities in the immune complexes were measured in 
the in the presence of 200 mM AMP. Activities were calculated as picomoles of 
phosphate incorporated into the SAMS peptide per min, per milligram of protein 
subjected to immunoprecipitation (pmol/min/mg).  Acetyl CoA carboxylase 
(ACC) was affinity purified by incubating the post-AMPK immunoprecipitation 
supernatants in Streptavidin Sepharose High Performance beads (Amersham 
Biosciences, Uppsala, Sweden) for 1 h at 4°C.  Aliquots of the 
immunoprecipitated (AMPK), and affinity purified (ACC) proteins were 
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electrophoresed using 10%, or 7.5% SDS-PAGE, respectively and transferred 
to PVDF membranes.  Site-specific phosphorylation was then detected by 
immunoblotting with anti-phospho-Thr172 (AMPK) or anti-phospho-Ser218 
(ACC) antibodies.  The membranes were stripped (Restore Western Blot 
Stripping Buffer, Pierce Biotechnology, Inc.), and total AMPK protein contents 
were determined using antibodies specific for the AMPK α1, and α2 isoforms.  
Total ACC protein was determined using a Streptavidin-HRP conjugate 
(Invitrogen Australia Pty. Ltd.). 
Western Blotting 
RQ muscle lysates (60 µg) were solubilized in Laemmli buffer, separated 
by SDS-PAGE, and transferred to PVDF membranes (BioRad Laboratories, CA, 
USA).  The membranes were blocked, and incubated overnight at 4°C with 
antibodies specific for either add phospho-Akt ser473, Akt, Akt1, Akt2 (1:1000; 
Cell Signaling # 4058, 9272, 2967, 2962), AS160 (a gift from David James, 
Garvan Institute, Sydney), PGC-1 (Chemicon International, Inc. AB3242),  or 
GLUT4 (Biogenesis, UK  4670-1704).  The immunoreactive proteins were 
detected with enhanced chemiluminescence (Amersham Biosciences) and 
quantified by densitometry.   FAT/CD36 and FABPpm content were determined 
as previously described (Bonen et al. 1998). 
Analysis of intramuscular muscle lipids 
Skeletal muscle triacylglycerol (TAG), diacylglycerol (DAG) and ceramide 
contents were analysed as previously described in chapter three.  Briefly, 
freeze-dried muscle was powdered, and cleaned of all visible connective tissue 
and blood under magnification.  Skeletal muscle TAG (glycerol) content was 
determined fluorometrically, following Folch lipid extraction and saponification of 
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a portion of dry, powdered tissue.  DAG and ceramide content were quantified 
using the DAG Kinase method on a separate aliquot of tissue. 
Blood Metabolite Measurements 
Blood was analysed for fasting concentrations of glucose, insulin, 
adiponectin and free fatty acids (FFA). Serum was obtained by centrifugation of 
whole blood collected at the time of euthanasia, and stored at –80°C until 
analysis.  Serum glucose was determined using the MediSense2 Blood Glucose 
Testing system (MediSense Australia Pty., Ltd., Melbourne).  Serum insulin and 
adiponectin levels were determined using enzyme immunoassay kits (Sensitive 
Rat Insulin RIA kit, Linco Research; Mouse/Rat Adiponectin ELISA kit, Otsuka 
Pharmaceutical Co., Ltd.).  Serum FFA were determined using an enzymatic 
colorimetric method (NEFA C, Wako Chemicals, USA, Inc.). 
5.2.1 Statistical Analysis 
Results are presented as mean ± SEM.  Differences arising from dietary 
interventions were determined using an unpaired t-test (CF CON vs. HF CON).  
Differences between HF treatment groups were determined using a one-way 
analysis of variance with a Student-Newman-Keuls post-hoc test (SigmaStat 
version 3.1.1.). 
5.3 Results 
Body mass was increased by high-fat feeding and RSG treatment, but 
was decreased by EX (Table 1, P<0.05).  Changes in body mass were mirrored 
by changes in epididymal fat pat mass (Table 5.1).  Serum adiponectin 
concentration was elevated in HF RSG (P=0.03 vs. HF CON), and decreased in 
HF EX (P=0.04 vs. HF CON).  Serum free fatty acid (FFA) concentration was 
also decreased in both HF EX and HF EX RSG (P<0.02 vs. HF CON).  
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Table 5. 1 Effect of chronic exercise, and/or RSG treatment on body 
mass, fat pad mass, and fasting serum composition in fat-fed rats. 
 CF CON HF CON HF EX HF RSG HF EX RSG 
Body 
mass (g) 
434±6 464±8 * 417±5 † 470±8 ‡ 404±7 §†
Epididymal fat 
pad mass (g) 
6.2±0.3 10.7±0.6 * 6.8±0.4 † 10.3±0.5 ‡ 6.6±0.3 §†
Serum: 
Glucose (mM) 14.9±1.2 13.9±0.9 13.7±1.0 13.35±1.3 10.0±1.1 †
Insulin (ng/mL) 1.23±0.25 1.21±0.24 0.84±0.16 1.25±0.21 0.88±0.20 
 Adiponectin 
(µg/mL) 
2.09±0.30 3.46±0.80 1.58±0.26 5.83±0.65 †‡ 3.70±0.55 §
FFA (mM) 0.89±0.16 0.60±0.10 0.33±0.05 † 0.50±0.05 0.29±0.04 †
 
*P<0.05 vs. LN CON, †P<0.05 vs. HF CON, ‡P<0.05 vs. HF EX, §P<0.05 vs. 
HF RSG (n=8/group). 
 
 
Glucose metabolism 
Insulin-stimulated glucose transport in the red quadriceps muscle of HF 
controls (HF CON) was reduced by ~37% (P=0.005; Fig 5.1A) compared to 
chow-fed controls (CF CON) and was impaired a further ~32% (P=0.05) in HF 
RSG.  Exercise training restored insulin-stimulated glucose transport in fat-fed 
and RSG-treated animals (P<0.05).  Basal muscle glycogen content (Fig 5.3A) 
was increased in HF EX and HF EX RSG (P<0.05, vs. HF CON), and 
decreased with HF RSG (P<0.05, vs. HF CON).    
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Figure 5. 1  3H-3-O-methylglucose and 14C-palmitate hindlimb perfusions.  
Muscle glucose transport (A) was measured in the red quadriceps muscle 
following hindlimb perfusion with 3H-3-O-methylglucose in the presence of 
insulin (500 µU/mL).  Average14C-palmitate uptake (B) and 14CO2 production 
due to 14C-palmitate oxidation (C) were calculated using differences in arterial 
and venous perfusate concentrations during a 40 min hindlimb perfusion with 
500 µM palmitate.  Significant differences between groups (P<0.05; n=8/group) 
are indicated by the P values listed on the figure. 
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AMPK activity 
AMPKα1 activity was unchanged by high-fat feeding, but increased 
~30% in HF EX (P=0.01 vs. HF CON) and ~37%  in HF EX RSG (P=0.006 vs. 
HF CON) [Fig 5.2A].  AMPK α2 activity was increased ~36% by high-fat feeding 
(P=0.03, HF CON vs. CF CON), but was not altered by EX or RSG (Fig 5.2B).  
Changes in both AMPK -α1, and -α2 activities were associated with similar 
changes in the total protein levels of these isoforms (P<0.05, Fig 5.2C).  
Phosphorylation of AMPK α1 at T172 was similar between HF CON and HF 
RSG, but tended to increase in HF EX, and HF EX RSG (P=0.1 vs. HF CON).  
HF-induced increases in activity and protein levels in the AMPKα2 isoform were 
associated with increased phosphorylation of the enzyme at T172 (CF CON vs. 
HF CON, P=0.01).  We also examined the protein levels and phosphorylation 
status of the AMPK substrate, acetyl Co-A carboxylase (ACC).  Although no 
changes in the total protein level of ACC were observed (Fig 5.2C) there was a 
significant increase in the level of phosphorylation of the enzyme at S218 with 
high-fat feeding (CF CON vs. HF CON, P=0.04).   
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 Figure 5. 2 Skeletal muscle AMP-activated protein kinase (AMPK) activity 
and protein expression.   
AMPKα1 (A) and AMPKα2 (B) activities (pmol/min/mg) were measured using 
the SAMS peptide assay in protein isolated by immunoprecipitation of muscle 
lysates.  Relative levels of isoform-specific AMPK T172 phosphorylation and 
total protein, as well as acetyl CoA carboxylase (ACC) S218 phosphorylation 
and total protein were quantified using Western blot analysis and densitometry 
(C).  Significant differences between groups (P<0.05; n=8/group) are indicated 
by the P values listed on the figure. 
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Lipid Metabolism: 
Muscle triacylglycerol (TAG; Fig 5.3B) and diacylglycerol (DAG; Fig 
5.3D) content increased 20% and 13%, respectively in HF RSG (P<0.05 vs. HF 
CON), but were normalized by EX (HF RSG vs. HF EX RSG; P<0.05).  Muscle 
ceramide (CER) content increased ~23% with high-fat feeding (CF CON vs. HF 
CON, P=0.01), but was unaffected by either EX or RSG treatment.   Increased 
muscle lipid storage was associated with increased 14C-palmitate uptake in the 
perfused hindlimb (Fig 5.1B).  Palmitate uptake was ~40% higher in HF CON 
compared with CF CON (P=0.04), and increased a further 40% in HF RSG 
(P=0.03).  RSG-induced increases in palmitate uptake were associated with a 
~50% increases in skeletal muscle FAT/CD36 protein content in both HF RSG 
and HF EX RSG (P<0.05 vs. HF CON; Fig 5.4A).  No changes in the protein 
content of FABPpm were observed (Fig 5.4B), although there was a tendency 
for RSG treatment to reduce this putative FA transporter.  Although 14C-
palmitate uptake was not increased in HF EX (Fig 5.1B), a 2-fold increase in 
14CO2 production was observed (P=0.03 vs. HF CON; Fig 5.1C), suggesting 
that increased lipid oxidation may be a mechanism responsible for normalised 
lipid levels in HF EX RSG.  Increased lipid oxidation with exercise training was 
associated with ~30% increase in the expression of PGC-1 (Fig 5.4C) in both 
HF EX (P=0.03 vs. HF CON) and HF EX RSG (P=0.07 vs. HF CON).  In the 
liver, TAG was increased 36% by high-fat feeding (P=0.03), but was normalized 
in all three treatment groups (HF EX, HF RSG, HF EX RSG, P<0.001 vs. HF 
CON; Fig 5.3F). 
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 Figure 5. 3 Skeletal muscle carbohydrate and lipid storage.   
Muscle glycogen (A), triacylglycerol (B), ceramide (C) and diacylglycerol (D) 
content were quantified in separate aliquots of red quadriceps (RQ) muscle.  In 
order to determine whether muscle samples were contaminated with significant 
amounts of intermyocellular adipocytes,  protein aliquots from both adipose 
tissue (15 µg), and muscle (80 µg) were separated by SDS-PAGE and probed 
for the adipose-specific proteins Perilipin A/B (E).  Liver triacylglycerol was also 
measured (F).  Significant differences between groups (P<0.05; n=8/group) are 
indicated by the P values listed on the figure. 
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 Figure 5. 4 Skeletal muscle lipid transporters and PGC-1 content.   
Relative protein levels of FAT/CD36 (A), FABPpm (B) and PGC-1 (C) were 
quantified using Western blot analysis and densitometry.   Significant 
differences between groups (P<0.05; n=8/group) are indicated by the P values 
listed on the figure. 
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Akt/AS160 
Compared to chow-fed controls (CF CON), total Akt protein was reduced 
~25% by high-fat feeding (HF CON; P=0.01) and was restored by EX (HF CON 
vs. HF EX; P=0.007; Fig 5.5A).  The increase in total Akt was entirely 
attributable to an increase in the Akt1 isoform (Fig 5.5C), which was elevated 
~50% by exercise training (HF CON vs. HF EX; P=0.04).  RSG did not change 
Akt1 protein content, and appeared to blunt the EX-induced increase in Akt1 
(HF EX vs. HF EX RSG; P=0.04).  No changes in the Akt2 isoform (Fig 5.5D) 
were observed after either treatment.  Phosphorylation of total Akt at the S473 
residue (Fig 5.5B) was also altered by EX, with a 50% decrease in HF EX 
(P=0.01 vs. HF CON).  AS160 protein was elevated ~15% in HF (CF CON vs. 
HF CON; P=0.004) and was normalized in both HF EX (P=0.04) and HF EX 
RSG (P=0.03; Fig 5.6A).  GLUT4 protein content was decreased ~20% in HF 
CON (P=0.007), but was increased ~50% and ~40% in HF EX and HF EX RSG, 
respectively (P<0.001; Fig 5.6B) 
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 Figure 5. 5 Isoform-specific skeletal muscle Akt content.   
Relative protein levels of total Akt 1/2 (A), Akt phosphorylation at S473 (B), as 
well as the isoform-specific content of Akt 1 (C), and Akt 2 (D) were quantified 
using Western blot analysis and densitometry.  Significant differences between 
groups (P<0.05; n=8/group) are indicated by the P values listed on the figure.  
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 Figure 5. 6 Skeletal muscle AS160 and GLUT4 content.   
Relative protein levels of total AS160 (A), and total GLUT-4 (B) protein were 
quantified using Western blot analysis and densitometry.   Significant 
differences between groups (P<0.05; n=8/group) are indicated by the P values 
listed on the figure.  
 
5.4 Discussion 
It is well-established that chronic Rosiglitazone treatment improves 
whole-body insulin sensitivity (Malinowski and Bolesta 2000).  Less clear, 
however, is whether this enhanced insulin action is directly attributable to the 
effects of Rosiglitazone on skeletal muscle, or other insulin-sensitive tissues.  In 
the present study, we observed that exercise training, but not Rosiglitazone 
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treatment reversed skeletal muscle insulin-resistance associated with a high-fat 
diet.  Contrary to our hypothesis, Rosiglitazone treatment decreased insulin-
stimulated glucose transport (P=0.05, Fig 5.1A) in the perfused hindlimb 
compared to HF CON.  Hindlimb perfusion allows the calculation of insulin-
stimulated glucose transport in specific skeletal muscle groups while minimizing 
interference from systemic factors or other insulin sensitive tissues (i.e. hepatic 
glucose output).    
Few other investigations have determined the effect of chronic 
Rosiglitazone treatment directly on skeletal muscle glucose transport.  Shen et 
al. (2004) recently reported that 2 wk of Rosiglitazone treatment increased 
insulin-stimulated glucose transport in the isolated EDL muscle of db/db mice 
(Shen et al. 2004).  Unlike humans with insulin-resistance (Wojtaszewski et al. 
2005), genetically-induced leptin receptor-deficient and leptin-deficient animal 
models of insulin resistance (i.e. fa/fa Zucker, ob/ob mouse) have well-
documented impairments in basal skeletal muscle AMPK activity (Buhl et al. 
2002; Yu et al. 2004; Sriwijitkamol et al. 2006).  Impaired AMPK activity and 
insulin sensitivity in these models can be reversed by AICAR administration 
(Buhl et al. 2002; Yu et al. 2004), or Rosiglitazone treatment (as described in 
chapter four).   The absence of basal AMPK deficiency and Rosiglitazone-
induced changes in AMPK activity in the present study using a high-fat fed rats 
provides a likely mechanism for the absence of a Rosiglitazone-induced 
improvement in muscle insulin sensitivity.  While the use of a leptin receptor-
deficient model of insulin resistance (db/db mouse) by Shen et al. (2004) may 
provide some explanation for these inconsistent results, it should also be noted 
that the doses of Rosiglitazone (30 mg/kg) and insulin (104 µU/mL) used in that 
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study were 15- and 20-fold higher, respectively, than those employed in the 
present study.  
Studies examining the effect of Rosiglitazone on insulin-signalling in 
skeletal muscle have also produced variable results.  Miyazaki et al. (2003) 
observed that chronic Rosiglitazone treatment (8 mg/day) for 16 wk resulted in 
increased skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation and 
p85 association in patients with type 2 diabetes (Miyazaki et al. 2003).  In 
contrast, others have observed no enhancement in the IRS-1/PI 3-
kinase/Akt/AS160 signalling pathway after 26-wk of Rosiglitazone treatment (8 
mg/day) in the skeletal muscle of patients with newly-diagnosed type 2 diabetes 
(Karlsson et al. 2005a).   In the present study we saw no change in the total 
protein levels of Akt (Fig 5.5), AS160 or GLUT4 (Fig 5.6) following 4 wk of 
Rosiglitazone treatment.  In contrast, exercise training normalized impairments 
to the Akt/AS160/GLUT4 signalling pathway caused by high-fat feeding.  It has 
recently been observed that contraction (Bruss et al. 2005; Kramer et al. 2006), 
or a single bout of endurance exercise (Deshmukh et al. 2006)  can acutely 
increase AS160 phosphorylation in muscle.  To our knowledge, the present 
investigation is the first to demonstrate changes in AS160 expression due to 
chronic high-fat feeding and exercise training.  Our results suggest that high-fat 
feeding may impair insulin-stimulated glucose uptake by downregulating distal 
components of the insulin-receptor signalling cascade that lead to GLUT4 
translocation and that these impairments are reversed by exercise training, but 
not Rosiglitazone treatment.  In contrast, Hevener et al. (2000) observed 
additive effects of exercise training and Troglitazone treatment on GLUT4 
content in the skeletal muscle of obese Zucker rats.  Again, this apparent 
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discrepancy is likely attributable to the use of a leptin-receptor deficient model in 
Hevener et al. (2000) and a fat-fed model in the present investigation. 
Although exercise training upregulated insulin-stimulated glucose 
transport as well as the expression of key components of the signalling pathway 
leading to GLUT4 translocation, a decrease in Akt phosphorylation at Ser473 
was also observed in response to this intervention (Fig 5.5B).  An increase in 
muscle insulin-stimulated glucose transport  in the face of decreased Akt 
phosphorylation appears paradoxical, yet discrepancies between Akt activation 
and upstream insulin signalling (i.e. PI-3 Kinase activation) have previously 
been reported in several different models of insulin resistance (Kurowski et al. 
1999; Song et al. 1999; Kim et al. 2000).  Considering the complex regulation of 
Akt and its involvement in a range of signalling pathways (Taniguchi et al. 2006) 
it is likely that its phosphorylation state reflects the additive input of a number 
pathways.   
In addition to exercise-induced changes in Ser473 phosphorylation, we 
observed increased expression of the Akt1 isoform after exercise training.  It 
has been proposed that Akt2 plays the predominant role in insulin-stimulated 
glucose uptake (Bae et al. 2003; Brozinick et al. 2003), while Akt1 is involved in 
the regulation of protein synthesis and muscle hypertrophy (Nader 2005).  
However, Akt1 has recently been implicated in the regulation of FA uptake in 
skeletal muscle using isoform-specific siRNA based gene silencing (Bouzakri et 
al. 2006).   More investigation into the specific function of Akt1 in exercise 
training adaptations in skeletal muscle is needed. 
The effect of exercise training and Rosiglitazone treatment on AMPK 
signalling was also examined in the skeletal muscle of high fat-fed rats.  High fat 
feeding resulted in a ~36% increase in AMPKα2 activity (Fig 5.2B), which was 
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not further augmented by Rosiglitazone treatment.  This in vivo finding of 
increased AMPK activity with high-fat feeding is in agreement with previous 
work demonstrating that acutely increasing FA availability stimulates AMPK 
activity, ACC phosphorylation and palmitate oxidation in L6 myotubes (Fediuc et 
al. 2006; Watt et al. 2006).   Furthermore, it was also observed that the FA-
induced increase in AMPK activity was attributable to activation of the α2 
isoform of AMPK which was associated with increased ACC phosphorylation, 
but not increased glucose transport.  In contrast, AMPKα1 activity was not 
affected by diet, but was increased by exercise training, which was associated 
with improved insulin-stimulated glucose transport and glycogen storage.  
These observations are consistent with others reporting upregulation of 
AMPKα1 following exercise training in humans with type 2 diabetes 
(Wojtaszewski et al. 2005) and animal models of insulin resistance 
(Sriwijitkamol et al. 2006).  The results of the present study point to the AMPK α 
subunit isoforms having distinct roles, with AMPKα2 activity being responsive to 
increased FA availability, and AMPKα1 activity being linked to exercise training-
induced changes in glycogen storage and insulin-sensitivity.   
 The effect of Rosiglitazone treatment on skeletal muscle lipid storage is 
equivocal, as previous investigations have reported a decrease (Hockings et al. 
2003; Jucker et al. 2003; Ye et al. 2003), an increase (Muurling et al. 2003; 
Todd et al. 2006), or no effect (Oakes et al. 1994; Oakes et al. 1997b; 
Mayerson et al. 2002; Coort et al. 2005) on muscle TAG content.  In the present 
study, 4 wk rosiglitazone treatment resulted in a 20% increase in muscle TAG 
content (Fig 5.3B).   We attribute this increase in lipid storage to an increase in 
lipid uptake (Fig 5.1B) resulting from a Rosiglitazone-induced upregulation of 
FAT/CD36 (Fig 5.4A).  These findings are consistent with those of Wilmsen et 
 114
al. (2003), who found that 4-day treatment of skeletal muscle cells taken from 
type 2 diabetic subjects resulted in a 2.5-fold increase in FAT/CD36 (Wilmsen et 
al. 2003).   Increased palmitate uptake without a concomitant increase in FA 
oxidation would be expected to increase the storage of lipids in skeletal muscle.  
Although a Rosiglitazone-induced increase in 14CO2 production during hindlimb 
perfusion with 14C-palmitate was observed, this was likely due to increased 
uptake, rather than elevated oxidative capacity.  In contrast, exercise training 
increased palmitate oxidation without increasing palmitate uptake, suggesting 
that the capacity to oxidize FA was upregulated in these animals.  Increased 
palmitate oxidation was associated with elevated PGC-1 expression in both HF 
EX and HF EX RSG (Fig 5.4C).  Increased capacity to oxidise FA provides a 
potential mechanism by which exercise prevents the increase in muscle lipid 
storage observed in animals treated with Rosiglitazone alone. 
 It has been suggested that Rosiglitazone acts to improve insulin 
sensitivity by increasing the uptake of FA into adipocytes, thereby reducing the 
availability of lipids for accumulation in other insulin-sensitive tissues, such as 
skeletal muscle (Hockings et al. 2003; Jucker et al. 2003).  However, it has 
been previously described in chapter three of this thesis and by others 
(Muurling et al. 2003) that Rosiglitazone improves whole-body insulin sensitivity 
despite exacerbating the accumulation of lipids in skeletal muscle.  The results 
of the present study corroborate these findings, and provide direct mechanistic 
evidence that chronic PPARγ activation may promote lipid storage in muscle, as 
it does in adipose tissue, by upregulating lipid transport.  Exercise training in 
combination with Rosiglitazone treatment prevented the Rosiglitazone-induced 
accumulation of lipids and decrease in insulin sensitivity despite increased lipid 
uptake and CD36 expression in this treatment group.  Thus, it appears that 
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exercise training imparts a “metabolic flexibility” (Kelley 2002) allowing skeletal 
muscle to deal with increased lipid availability without compromising glucose 
metabolism.   
 Hevener et al. (2000) have previously demonstrated that combined TZD 
(Troglitazone) treatment and exercise training have additive beneficial effects 
on whole-body insulin sensitivity.  Rosiglitazone did not improve skeletal muscle 
insulin sensitivity in the present study.  However, the observation that lipid 
accumulation was reduced in the liver of Rosiglitazone-treated animals raises 
the possibility that this organ acts as a potential target for its insulin-sensitising 
actions.  In support of this contention, Gastaldelli et al. (2006), have recently 
reported that Rosiglitazone treatment (8 mg/day for 12 weeks) decreased 
gluconeogenesis in patients with type 2 diabetes (Gastaldelli et al. 2006).  
Exercise-induced improvements in skeletal muscle insulin sensitivity, combined 
with the potential for Rosiglitazone to improve hepatic insulin action, provides a 
potential mechanism for the additive improvements in whole-body insulin action 
(following combined TZD treatment and exercise training) observed by Hevener 
et al (2000).   Further investigation into the effects of Rosiglitazone treatment on 
lipid and glucose metabolism the liver, and other insulin-sensitive tissues are 
needed. 
 In conclusion, evidence has been provided that exercise training, but not 
Rosiglitazone treatment reverses skeletal muscle insulin resistance induced by 
lipid oversupply. Rosiglitazone is a potent whole-body insulin sensitiser, and 
exercise training reverses Rosiglitazone-induced impairments to skeletal 
muscle glucose transport.  Therefore, the combined prescription of 
Rosiglitazone and exercise training is likely to be a more effective therapeutic 
option for individuals with insulin resistance than either treatment alone.  
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CHAPTER SIX: General Summary and Discussion 
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 The primary aim of the studies undertaken for this thesis was to enhance 
our understanding of the mechanisms by which two common therapies for the 
treatment of insulin resistance, Rosiglitazone and exercise training, reverse 
aberrant lipid handling and improve insulin sensitivity in skeletal muscle.  
Several aspects of skeletal muscle lipid metabolism were examined with 
respect to their potential to improve glucose homeostasis in two distinct animal 
models of insulin resistance.  The ability of Rosiglitazone and exercise training 
to alter the regulation of fatty acid transport, storage and utilisation was 
determined in three independent, but related investigations.       
 The first two studies (chapters three and four) used a genetically-induced 
model of insulin resistance, the obese Zucker rat, to determine the means by 
which Rosiglitazone alters skeletal muscle insulin sensitivity.  Although “lipid 
steal” from skeletal muscle has been described as a potential mechanism by 
which PPARγ agonists improve insulin sensitivity, several studies have unveiled 
a disassociation between IMTG content and insulin sensitivity following 
Rosiglitazone treatment.  This raises the possibility that rather than decreasing 
IMTG per se, Rosiglitazone may act to improve insulin sensitivity by reducing 
the accumulation of lipid intermediates that have a more direct mechanistic link 
to impairments in skeletal muscle insulin signal transduction, such as ceramide 
and diacylglycerol.   
 Contrary to this hypothesis, Rosiglitazone treatment increased the levels 
of ceramide and diacylglycerol in skeletal muscle despite improving whole-body 
insulin sensitivity.  In addition, Rosiglitazone treatment decreased the activity of 
hormone-sensitive lipase and altered the composition of the fatty acid pool in 
skeletal muscle.  These results were the first to suggest that Rosiglitazone may 
be a regulator of lipid metabolism in skeletal muscle, and that its lipid-altering 
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actions in this tissue may not simply be secondary to a reduction in plasma lipid 
availability.  The observation that Rosiglitazone treatment improved glucose 
tolerance in the face of increased skeletal muscle lipid metabolites (TAG, DAG, 
ceramide) led to the conclusion that reduced skeletal muscle lipid accumulation 
is not the mechanism by which Rosiglitazone improves insulin sensitivity.  
 In light of this finding, it seemed likely that Rosiglitazone treatment 
improved skeletal muscle insulin sensitivity by an alternative and possibly, 
PPARγ-independent, mechanism.   In this regard, it had been previously 
observed that Rosiglitazone could stimulate AMPK activity in vitro. However, the 
effects of chronic Rosiglitazone treatment on skeletal muscle AMPK in vivo 
were not known.  Given the potential for AMPK to improve both glucose and 
lipid metabolism in skeletal muscle, AMPK activation is one mechanism by 
which Rosiglitazone could improve insulin sensitivity independent of skeletal 
muscle lipid accumulation. Accordingly, the study described in chapter four 
determined whether Rosiglitazone could induce chronic increases in AMPK 
activity in the skeletal muscle of obese Zucker rats.  
  The results of this study provided the first evidence that chronic 
Rosiglitazone treatment can increase skeletal muscle AMPK activity in vivo.  
The skeletal muscle of obese Zucker rats displayed decreased activity and 
expression of the AMPKα2 isoform, both of which were normalised to the level 
of lean controls following chronic Rosiglitazone treatment.  ACC 
phosphorylation paralleled the changes in AMPKα2 activity, while no changes to 
the AMPKα1 isoform were observed.  These results suggest that there may be 
an isoform-specific role for AMPKα2 in the regulation of skeletal muscle lipid 
metabolism. 
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 The capacity to oxidise fatty acids is a better predictor of insulin 
sensitivity than intramuscular lipid accumulation.  Therefore, it was 
hypothesised that Rosiglitazone-induced increases in AMPK activity may 
improve skeletal muscle insulin-sensitivity via AMPK-induced increases in lipid 
oxidation.  Stimulation of skeletal muscle AMPK activity and increased capacity 
to oxidize fatty acids is a response typically observed after exercise training.  In 
this regard, it is possible that Rosiglitazone treatment may exert an “exercise-
like” effect in skeletal muscle.  In order to test this hypothesis, the study 
described in chapter five determined the independent and interactive effects of 
Rosiglitazone treatment and exercise training on AMPK activation and a variety 
of direct and indirect measures of fatty acid oxidation.  It was hypothesised that 
exercise training combined with Rosiglitazone treatment would result in additive 
improvements in skeletal muscle insulin sensitivity, AMPK activity and fatty acid 
oxidation compared to either treatment alone.  These experiments were 
performed in a less severe model of insulin resistance (the high-fat fed rat), and 
in situ measurements of insulin stimulated glucose transport and fatty acid 
oxidation were undertaken using hindlimb perfusion, allowing for muscle-
specific effects to be determined. 
 Insulin-stimulated glucose uptake was reduced by high-fat feeding, but 
insulin sensitivity was restored by exercise training.  In contrast, Rosiglitazone 
treatment tended to exacerbate the insulin resistance associated with high-fat 
feeding, resulting in even lower insulin-stimulated glucose uptake.  In hindlimb 
muscle perfused with palmitate rather than glucose the inverse relationship was 
observed: palmitate uptake was elevated by high-fat feeding and increased 
even further with Rosiglitazone treatment.  Increased palmitate uptake in this 
tissue corresponded with increased palmitate oxidation in Rosiglitazone-treated 
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animals, whereas exercise trained animals displayed increased oxidation 
despite having levels of palmitate uptake similar to chow-fed control animals.  
Rosiglitazone-induced increases in palmitate uptake were associated with 
skeletal muscle lipid storage and increased expression of the putative FA 
transporter, CD36.   The results from this study provide direct mechanistic 
evidence to show that chronic PPARγ activation may promote lipid storage in 
muscle, as it does in adipose tissue, by upregulating lipid transport.   
 The results from this experiment also provided new evidence for the 
distinct roles of the AMPK alpha subunit isoforms in glucose and lipid 
metabolism in skeletal muscle.  AMPKα1 activity was increased by exercise 
training and was associated with increased insulin-stimulated glucose uptake, 
glycogen content and PGC-1 expression.  In contrast, AMPKα2 activity was 
elevated by high-fat feeding and was associated with increased ACC 
phosphorylation.  Importantly, no further increase in AMPKα2 activity was 
observed in response to Rosiglitazone treatment suggesting that this effect was 
specific to the leptin-receptor and AMPK deficient Zucker rat. 
 This study also provided novel information with respect to a potential 
mechanism by which glucose metabolism is downregulated by chronically 
elevated fatty acid availability. High-fat feeding increased skeletal muscle 
AS160 expression in conjunction with decreased GLUT4 expression, which 
would be expected to reduce insulin-stimulated glucose transport.  Importantly, 
exercise training was shown to reverse these impairments, even in the face of 
persistently elevated fatty acid availability.   
 The results from this final study demonstrated that exercise training 
simultaneously increased the oxidation of lipids and the uptake and storage of 
glucose in the skeletal muscle of fat-fed rats.  In contrast, Rosiglitazone 
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treatment resulted in increased fatty acid uptake, which appeared to further 
impair skeletal muscle glucose transport.  Exercise training in combination with 
Rosiglitazone treatment prevented the Rosiglitazone-induced accumulation of 
lipids and decrease in insulin sensitivity despite increased lipid uptake and 
CD36 expression in this treatment group.  Thus it appears that exercise training 
imparts a “metabolic flexibility” allowing skeletal muscle to deal with increased 
lipid availability without compromising glucose metabolism. 
 In summary, the results from the studies undertaken for this thesis 
provide novel information regarding the mechanisms of action of two insulin-
sensitising therapies, exercise training and Rosiglitazone treatment, in skeletal 
muscle.  Several questions remain that should be addressed by future work.  
For example, as Rosiglitazone did not improve skeletal muscle insulin sensitivity 
in a high-fat fed model (chapter five), it is not clear how it was effective in 
improving insulin sensitivity in other tissues.  The observation that lipid 
accumulation was reduced in the liver of Rosiglitazone-treated animals raises 
the possibility that this organ acts as a potential target for its insulin-sensitising 
actions.  Further investigation into the effects of Rosiglitazone treatment on lipid 
and glucose metabolism in this, and other insulin-sensitive tissues are needed.  
In addition, future research should determine the molecular mechanisms by 
which exercise training improves metabolic flexibility by allowing for the 
simultaneous upregulation of both glucose and lipid metabolism.  Such 
information may provide clues for the development of more effective insulin 
sensitising agents that specifically target skeletal muscle.  The results from this 
thesis suggest that chronic AMPKα1 activation may be involved in this process, 
but further investigation possibly involving skeletal muscle cell culture or 
isoform-specific AMPK knockout models are needed to confirm this hypothesis.  
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Continued discovery of the factors that lead to skeletal muscle insulin 
resistance, and the mechanisms by which currently available insulin-sensitising 
agents act to overcome these impairments may lead to the development of 
more effective treatments for this disease.  Given the increasing prevalence of 
insulin resistance and type 2 diabetes world-wide, it seems unlikely that 
researchers in this field will run out of work in the near future.    
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